Protocol: I8F-MC-GPHV 
 
 
 
 
A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric 
Participants (6 years to 11 years) with Obesity  
 
 
  
[STUDY_ID_REMOVED] 
 
 
 
 
Approval Date:  16-Nov-2023 
CONFIDENTIAL  I8F-MC-GPHV (e) 
1 Title Page   
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_10886]  (LY3298176 ), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company 
or its subsidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercia lly confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4  and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Protocol Title:  A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the 
Treatment of Pediatric Participants (6 y ears to 11 years) with Obesity . 
Protocol Number:  I8F-MC-GPHV  
Amendment Number:  e 
Compound : Tirzepatide (LY3298176 ) 
Brief Title:  
Safety, Tolerability and Pharmacokinetics of Tirzepatide in Pediatric Participants with Obesity . 
Study Phase: 1 
Acronym : GPHV  
Sponsor Name:  [CONTACT_11028]:  Indian apolis, Indiana, [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number(s)  
IND: 139721  
Approval Date:  Protocol  Amendment ( e) Electronically  Signed and  Approved  by [CONTACT_10937].  
 
Document ID:  VV-CLIN -110264  
 
  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708707] Information will be provided separately   
 
  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
3 Protocol Amendment Summary of Changes T able  
DOCUMENT HISTORY  
Document  Date  
Amendment d  28-July-2023   
Amendment c  05-June -2023  
Amendment b  19-January -2023  
Amendment a  27-October -2022  
Original Protocol  30-June -2022  
Amendment [e]  
This amendment is considered to be substantial and was done for reducing potential safety risk 
of the participants  while ensuring/maximizing adequacy  and robustness of the data generated in 
the clinical study . 
Overall Rationale for the Amendment:  
This protocol is being amended  to narrow the range of body weight in Cohort 3 in order to 
generate additional safety, tolerability , and PK data of tirzepatide in participants with relatively 
lower  body weight. A lower limit was also selected for  the body weight as a conservative 
approach , based on available adult exposure data  from PK/PD modeling .  
Section # and 
Name  [CONTACT_543107] 1.1 
Synopsis – 
treatment 
arms and 
planned 
duration  Updated screening body weight 
for Cohort 3  
Participants with body weight in the range 
of 40 to 60 kg inclusive will be enrolled in 
Cohort 3 : 
 narrow body weight range is  
selected  to generate additional 
safety, tolerability , and PK data of 
tirzepatide in participants with 
relatively lower body weight  
 upper limit of 60 kg is selected to 
obtain data from  participants in 50 
to 60 kg range  who will  receive a 
starting dose of  mg tirzepatide 
in addition to data from Cohort 1  
which includes participants ≥50  kg 
 sentinel dosing in first  participants 
in the body weight range of [ADDRESS_708708] body 
weight range and sentinel dosing 
for Cohort 3  
Section 2.3 
Benefit/Risk 
Assessment  Deleted the text on ‘lower body 
weight’ for participants in Cohort 
3 
Section 4.1 
Overall 
Design  Updated text to include body 
weight range for Cohort 3  
 
Sentinel dosing will be used for  
participants in the body weight 
range of 40 to 50 kg in Cohort 3  
Section 4.2 
Scientific 
Rationale for Modified text on rationale for 
sentinel dosing  in Cohort 3  
Approved on 16 Nov 2023 GMT
CCI
CCI
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
4 Section # and 
Name  [CONTACT_543108] 4.[ADDRESS_708709] 
Complaints  Replaced the text on ‘SAEs and 
AE of special interest ’ with all 
adverse events  Accurately describes  what is being done 
in the study  
Section 10.7. 
Appendix 7  
Tanner 
Staging  Added the following: The 
assessment of sexual maturity in 
children should include an 
assessment of age, growth , and 
menstrual history in addition to 
Tanner Staging. In case of 
discordance between breasts or 
genitals vs pubic hair, the default 
should be breast or genitals . Assessment of sexual maturity should be 
based on both pubic hair and 
accompanying breast/testi cular changes   
Section 
10.12 
Appendix 12  Details on amendment (d) added   
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
5 Table of Contents   
1. Protocol Summary  ................................ ................................ ................................ ........ 10 
1.1. Synopsis  ................................ ................................ ................................ .......................... 10 
1.2. Schema  ................................ ................................ ................................ ............................ 13 
1.3. Schedule of Activities  ................................ ................................ ................................ .....14 
2. Introduction  ................................ ................................ ................................ ................... 18 
2.1. Study Rationale  ................................ ................................ ................................ ............... 18 
2.2. Background  ................................ ................................ ................................ ..................... 18 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 21 
3. Objectives and Endpoints  ................................ ................................ ............................ 22 
4. Study Design  ................................ ................................ ................................ .................. 23 
4.1. Overall  Design  ................................ ................................ ................................ ................ 23 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 23 
4.3. Justification for Dose  ................................ ................................ ................................ ......24 
4.4. End of Study Definition  ................................ ................................ ................................ ..24 
5. Study Population  ................................ ................................ ................................ ........... 25 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 25 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 26 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .29 
5.3.1.  Intensive Behavioral Therapy (IBT) for Chronic Weight 
Management in Children 6 -11 Years Old  ................................ ................................ .......29 
5.3.2.  Meals and Dietary R estrictions  ................................ ................................ ....................... 29 
5.3.3.  Substance Use: Caffeine, Alcohol, and Tobacco  ................................ ............................ 29 
5.3.4.  Activity and Vaccinations  ................................ ................................ ............................... 30 
5.4. Screen Failures  ................................ ................................ ................................ ................ 30 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 31 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 31 
6.1.1.  Administration Details  ................................ ................................ ................................ ....31 
6.1.2.  Medical Devices ................................ ................................ ................................ .............. 32 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 32 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 33 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 33 
6.5. Dose Modification  ................................ ................................ ................................ .......... 34 
6.5.1.  Data Review during the Study  ................................ ................................ ........................ 34 
6.6. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 35 
6.7. Treatment of Overdose  ................................ ................................ ................................ ...35 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....35 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 37 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 37 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_708710] to Follow -up................................ ................................ ................................ ............ 38 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708711] Circumference  ................................ ................................ ......... 49 
8.6. Genetics  ................................ ................................ ................................ .......................... 50 
8.7. Biomarkers  ................................ ................................ ................................ ...................... 50 
8.8. Immunog enicity Assessments ................................ ................................ ......................... 50 
8.9. Health Economics  ................................ ................................ ................................ ........... 50 
9. Statistical Considerations  ................................ ................................ ............................. 51 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....51 
9.1.1.  Multiplicity Adjustment  ................................ ................................ ................................ ..51 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 51 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 51 
9.3.1.  General Considerations  ................................ ................................ ................................ ...51 
9.3.2.  Pharmacokinetics  ................................ ................................ ................................ ............ 52 
9.3.3.  Safety Analyses  ................................ ................................ ................................ ............... 52 
9.3.4.  Evaluation of Immunogenicity  ................................ ................................ ....................... 52 
9.4. Inter im Analysis  ................................ ................................ ................................ .............. 53 
9.5. Sample Size Determination  ................................ ................................ ............................ 53 
10. Supporting Documentation and Operational Considerations  ................................ ..54 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 54 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 54 
10.1.2.  Informed Consent Process  ................................ ................................ .............................. 55 
10.1.3.  Data Protection ................................ ................................ ................................ ................ 55 
10.1.4.  Dissemination of Clinical Study Data ................................ ................................ ............. 56 
10.1.5.  Data Quality Assurance  ................................ ................................ ................................ ..56 
10.1.6.  Source Documents  ................................ ................................ ................................ .......... 57 
10.1.7.  Study and Site Start and Closure  ................................ ................................ .................... 58 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
7 10.1.8.  Publication Policy  ................................ ................................ ................................ ........... 58 
10.1.9.  Sample Retention  ................................ ................................ ................................ ............ 58 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 59 
10.2.1.  Blood Sampling Summary  ................................ ................................ .............................. 61 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ ............ [ADDRESS_708712] Complaints ................................ ................................ ........................ 66 
10.3.5.  Reporting of Serious Adverse Events  ................................ ................................ ............. 68 
10.3.6.  Regulatory Reporting Requirements  ................................ ................................ ............... 68 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ .......................... 69 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 69 
10.4.2.  Contraception Guidance ................................ ................................ ................................ ..69 
10.5.  Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 69 
10.6.  Appendix 6: Pancreatic Monitoring  ................................ ................................ ................ 71 
10.7.  Appendix 7: Tanner Staging  ................................ ................................ ........................... 73 
10.8.  Appendix 8: Laboratory Samples to be Obtained at the Time of a 
Systemic Hypersensitivity Event  ................................ ................................ .................... 75 
10.9.  Appendix 9: Stan dardized Protocols for the Measurement of 
Height, Weight, Waist Circumference, and Vital Signs  ................................ ................. 75 
10.10.  Appendix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  ................................ ................................ ............................. 78 
10.11.  Appendix 11: Abbreviations and Definitions  ................................ ................................ .82 
10.12.  Appendix 12: Protocol Amendment History  ................................ ................................ ..85 
11. References  ................................ ................................ ................................ ...................... 89 
 
  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708713] of Tables  
Table  Page  
Table GPHV.6.1.  Treatments Administered  ................................ ................................ .................. 31 
 
  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708714] of Figures  
Figure  Page  
Figure GPHV.1.1.  Illustration of enrollment and interim data review plan for Protocol 
I8F-MC-GPHV.  ................................ ................................ ................................ .13 
 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
10 1. Protocol Summary   
1.1. Synopsis   
Protocol Title:   
A Safety, Tolerability , and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants  (6 years 
to 11 years) with Obesity.  
Brief  Title:  Safety , Tolerability , and Pharmacokinetics of Tirzepatide in Pediatric Participants with Obesity .  
Rationale : 
Tirzepatide (LY3298176) is a dual glucose -dependent insulinotropic peptide receptor and glucagon -like peptide [ADDRESS_708715] to diet and exercise for chronic weight management in adult patients 
with or without type 2 diabetes mellitus ( T2DM ) who have an initial body mass index of greater than equal to 
30 kg /m2 (obes ity), or greater than equal to 27 kg/m2 (overweight). The dose of tirzepatide has been defined for 
adult s with obesity or overweight with one or more weight -related comorbidities , including T2DM , but data  are 
lacking in pediatric participants  with obesity  particula rly for the younger pediatric participants whose body weights 
are less likely to overlap with the body weights of adults with T2DM.  
Study I8F -MC-GPHV will assess the safety, tolerability , and pharmacokinetic  (PK) of tir zepatide administered 
weekly v ia the subcutaneous  (SC) route for 8 weeks  in pediatric participants  (age: 6 to 11 years) with obesity 
partitioned  according to weight (lower body weight : less than 50 kg; higher body weight : more than or equals to  50 
kg). 
Objectives  and Endpoint s: 
 
Objectives  Endpoints  
Primary  
 To evaluate tirzepatide safety and tolerability 
following SC injections of tirzepatide in 
pediatric participants with obesity   
 Incidence of adverse events, treatment -
emergent adverse events , and serious adverse 
events  
 
Secondary  
 To evaluate the PK profile of tirzepatide 
following SC injections in pediatric 
participants with obesity   
 Tirzepatide area under AUC 0-tau, Cmax from the 
population PK model  
Abbrev iations: AUC 0-tau = area under the concentration versus time curve  from time 0 to the end of the dosing 
interval ; Cmax = maximum concentration ; PK = pharmacokinetics; SC = subcutaneous . 
Overall Design :  
This is an investigator and participant blinded, randomized, placebo -controlled  safety, tolerability , and PK study in 
up to 3 cohorts of pediatric participants with obesity.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
11 Potential participants will be screened to assess their eligibility to enter the study within 28 days prior to Day 1.  
Participants will visit the clinic on Day 1 to be assessed and randomized and to e stablish baseline measurements.   
Participants will receive 8 weekly SC injections of  tirzepatide or placebo starting on Day 1 , remain inpatient within  
the clinical research unit ( CRU ) until at least Day [ADDRESS_708716]  4 weeks  but up to 6 weeks  upon 
early discontinuation.  
Safety will be assessed by [CONTACT_18651], electrocardiograms , safety laboratory tests, and the recording of adverse 
events ( AEs). PK blood samples for tirzepatide and immunogenicity samples will be collected.  
Treatment Arms and Planned Duration for an Individual Participant:  
Participants will be randomized to receive either tirzepatide or placebo in a  ratio. The study dura tion for 
individual participants, inclusive of screening , is expected to be approximately 19 weeks, divided as follows:  
 screening - up to 4 weeks prior to randomization   
 treatment period  - 8 weeks , and   
 follow -up - [ADDRESS_708717] dosing .  
Participants enrolled will be partitioned as follows:  
 Cohort 1: Higher weight cohort  – screening  body weight ≥50 kg   
 Cohort 2: Lower weight cohort  – screening  body weight <50 kg , and  
 Cohort 3 : Screening body weight between 40 to 60 kg inclusive . 
Number of  Participants:   
Approximately  participants  aged [ADDRESS_708718]  participants each, exposed to tirzepatide , for the weight categories <50 k g and ≥50 kg, 
respective ly. Participants who do not complete all the study procedures may be replaced to target the planned 
number of completers  specified in the sample determination section .  
Statistical Analysis:  
Primary safety statistical analyses will be conducted for all pa rticipants receiving the study drug whether or not they 
completed all protocol requirements.  
Tirzepatide concentration data will be analyzed using a population PK approach via nonlinear mixed -effects 
modeling with the NONMEM®  software. The main PK paramet ers for analysis will be maximum concentration  and 
area under the concentration versus time curve  from the population PK model .  
Safety parameters that will be assessed include safety laboratory parameters, vital signs, AEs, treatment -emergent 
AEs, and serious adverse events . The parameters will be listed and summarized using standard descriptive statistics. 
Additional analysis will be performed if warranted upon review of the data. All AEs related to study or protocol 
procedure will be listed , and if th e frequency of events allows, they will be also summarized using descriptive 
methodology.   
Physical examinations and electrocardiograms  will be performed for safety monitoring purposes and will be 
presented  as AEs when  clinically relevant findings are reported.  
Approved on 16 Nov 2023 GMT
CCI
CC
I
C
C
I
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708719] circumference.  
Data Monitoring Committee: No. 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
13 
Approved on 16 Nov 2023 GMT
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
14 1.3. Schedule of Activities   
Study Schedule Protocol I8F -MC-GPHV  
Visit Number  1 
Screening  2 
Baseline 
and 
Inpatient  3 4 5 6 7 8 9 10 11 12 13 = 
Final 
Follow -
up Early 
Discontinuation  
Week  -[ADDRESS_708720] Dose 
Days    
Visit Interval 
Tolerance 
(Days)   
Informed consent, 
assent, medical 
history, 
vaccination 
schedule , and full 
date of birth 
collection  X                           
Comments :  The informed consent form must be signed by [CONTACT_543055] (as appropriate per local 
requirements) must be signed by [CONTACT_543056] -specific tests/procedures are performed. Any vaccine which the participa nt 
is scheduled for as a part of immunization scheme must be captured in the concomitant medications pages of the CRF.  
Review and 
confirm I/E 
criteria  X Anytime 
predose                          
Pregnancy test 
(urine) - at site 
for females only  X  Any time  as deemed necessary by [CONTACT_543057] : At investigator’s clinical discretion (for example, there is reason to believe that the female participant is sexually active ) 
Enrolment and 
randomization    Day 1                          
Tanner staging  
(females only)  X P     P     X  X 
Intensive 
behavioral 
therapy   X X X 
Comments : Participant and at least one family member will be offered  IBT throughout the study. Starting at baseline , participants will be able 
to receive approximately 24 hours of therapy sessions. The frequency of IBT sessions will be flexible and at the discretion of the investigator . 
Inpatient visit    X                         
Approved on 16 Nov 2023 GMT
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
15 Visit Number  1 
Screening  2 
Baseline 
and 
Inpatient  3 4 5 6 7 8 9 10 11 12 13 = 
Final 
Follow -
up Early 
Discontinuation  
Week  -[ADDRESS_708721] Dose 
Days    
Visit Interval 
Tolerance 
(Days)   
Comments : Participant and accompanying adult will be admitted to the inpatient unit on morning of Day  [ADDRESS_708722] on Day 3. The 
inpatient stay may be extended by [CONTACT_543058] ’s clinical well -being.   
Outpatient visit  X  X X X X X X X X X X X X 
Comments : 
· For all participants - screening Visit 1, inpatient Visit [ADDRESS_708723] be performed in -clinic.  
· For all participants who discontinued early - early discontinuation visit must be performed in -clinic.  
· For Cohort [ADDRESS_708724] be highlighted in the informed consent and assent forms for Cohort 2.  
· All other outpatient visits, including final follow up (but not early discontinuation) may be performed remotely such as by t elemedicine or by 
[CONTACT_543059].  
Adverse events  & 
concomitant 
medication  
assessment  X X X X X X X X X X X X X X 
Physical 
examination  
/medical 
assessment  X P, before 
discharge  P      P        X  X X 
Comments : Full physical examination at screening. Thereafter, assessments performed to include medical review and targeted, symptom -driven 
examination, as appropriate. Additional assessments may be performed at investigator’s clinical discretion. P = predose measu re that can be 
performed any time prior to dosing.   
Height, weight, 
waist 
circumference , 
and body mass 
index  X P     P     X X X 
Comments : Height is required only during screening , Visit 1 , and Visit 12 . P = predose measure that can be taken any  time prior to dosing.  
Approved on 16 Nov 2023 GMT
CCI
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
16 Visit Number  1 
Screening  2 
Baseline 
and 
Inpatient  3 4 5 6 7 8 9 10 11 12 13 = 
Final 
Follow -
up Early 
Discontinuation  
Week  -[ADDRESS_708725] Dose 
Days    
Visit Interval 
Tolerance 
(Days)   
Supi[INVESTIGATOR_543038] X P, 8 
hours P    P   P  X X X 
Comments : Vital sign timing on Day [ADDRESS_708726] tirzepatide dosing (0 hours). P = predose measure that can be 
performed any time prior to dosing.   
Temperature  X P, 8 
hours          X X X 
Comments : Temperature timing on Day [ADDRESS_708727] tirzepatide dosing (0 hours) and may be measured via the oral, 
aural , or rectal route according to clinic’s local practice. P = predose measure that can be performed any time prior to dosing.  
Single, safety 12 -
lead ECG - at 
site X P, 8 
hours P    P   P  X  X 
Comments : ECG timing on Day [ADDRESS_708728] tirzepatide dosing (0 hours). Participants must be supi[INVESTIGATOR_543039] 3 
minutes prior to procedure and remain supi[INVESTIGATOR_57966]. P = predose measure that can be performed  any time prior to 
dosing.   
Clinical 
laboratory test 
(fasting)  X P     P     X  X 
Comments : Screening performed by [CONTACT_543060]. All others by a central laboratory. Clinical 
laboratory test on Day 1 is for baseline purpose , and results need not be reviewed prior to tirzepatide dosing. Additional unscheduled samples 
may be collected and assayed by [CONTACT_543061], at the investigator’s clinical discretion. P = predose measure that can be 
performed any time prior to dosing.  
Blood glucose 
monitoring or 
sampling for 
safety    Days 
1&2                         
Comments : On Days 1 and 2, blood glucose should be measured before bedtime. This can be measured using a glucose analyzer on site or local 
lab. Additional samples may be taken at the discretion of the investigator as clinically indicated or symptom -directed.   
Tirzepatide  
subcutaneous  
dosing to 
abdomen    Day 1  
(0 hr)  X X X 
(0 hr)    X 
(Increase 
dose 
level)  X 
(0 hr)   X X    
Approved on 16 Nov 2023 GMT
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
17 Visit Number  1 
Screening  2 
Baseline 
and 
Inpatient  3 4 5 6 7 8 9 10 11 12 13 = 
Final 
Follow -
up Early 
Discontinuation  
Week  -[ADDRESS_708729] Dose 
Days    
Visit Interval 
Tolerance 
(Days)   
Comments : Tirzepatide injection sites must be rotated along the 4 abdominal quadrants. Dosing may be performed by [CONTACT_543062] -
clinic visits. Self -administration by [CONTACT_543063].  The dose increase will happen at the 5th dose as indicated in Figure GPHV. 1.1  
Tirzepatide  
sampling for 
pharmacokinetics  
(hrs)    12, 24   P   X: within 
24 to 96 
hrs 
postdose    P X: 
within 
120 to 
168 hrs 
postdose   P X X X 
Comments : Sampling time is relative to the latest dosing time. The actual date and time of the sampling and the most recent SC inject ion 
administered prior to collecting the sample must be recorded. Day s 15, [ADDRESS_708730] be time -
matched with immunogenicity sampling. No sample collection is needed if the participant discontinued before receiving tirzepa tide. P = predose 
samples that should be collected within an hour prior to dosing.  
Immunogenicity 
sampling    P  P        P         X X 
Comments : Exact time of sampling must be recorded. Day s 15, [ADDRESS_708731] be time -matched 
with pharmacokinetic sampling. No sample collection is needed if the participant discontinued before receiving tirzepatide. P  = predose 
samples that should be collected within an hour prior to dosing.  
Abbreviations: BMI  = body mass index ; CRF  = case report form ; ECG = electrocardiogram; hrs = hour;  IBT = intensive behavioral therapy; I/E = inclusion and 
exclusion criteria ; P = predose.  
 
Approved on 16 Nov 2023 GMT
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
18 2. Introduction   
Obesity is a chronic disease and its increasing prevalence is a public health concern associated 
with rising incidence of T2DM , increased risk for premature death, and increased risk for some 
cancers (AMA 2013; Council on Science and Public Health 2013;  Lauby -Secretan et al. 2016). 
Although loss of 5% to 10% body weight through lifestyle approaches, based on caloric 
restriction, physical activity, and behavioral therapy, has been shown to reduce obesity -related 
CV risk factors, and in some cases, improve  health -related quality of life  (Mertens and Van Gaal 
2000; Knowler et al. 2002; Jensen et al. 2014; Kolotkin and Andersen 2017), lifestyle therapi[INVESTIGATOR_543040] 
(Dombrowski et al. 2014 ). Caloric restriction, for example, has been shown to lead to metabolic 
adaptive responses, including increases in hunger hormones, decreases in satiety factors 
(including GI peptides), increased appetitive drive and food intake, and lower energy exp enditure 
(Leibel et al. 1995; Sumithran et al. 2011). These adaptations are thought to work in concert to 
cause regain and poor durability of treatment. The addition of physical activity is essential and 
can help maintain weight loss, but generally, mainta ining lifestyle -induced weight loss is 
recognized as being more challenging than losing weight for individuals with obesity (Swift et 
al. 2018).  
Pharmacologic agents, in contrast to voluntary caloric restriction, can directly impact the 
physiology of energ y balance, including the regulation of food intake and/or energy expenditure, 
to drive toward a lower fat mass and body weight (Heymsfield et al. 2018). Some current or 
previously marketed weight -management medications have had a demonstrable effect on 
maintaining initial weight loss over time while on treatment (James et al. 2000; Smith et al. 
2010; Wadden et al. 2013). There is increasing recognition that adjunctive pharmacotherapy may 
be required to improve weight loss, weight maintenance, and health out comes in individuals with 
obesity (AMA 2013; Apovian et al. 2015).  
2.1. Study Rationale   
Tirzepatide (LY3298176) is a GIP receptor and GLP -[ADDRESS_708732] an initial BMI  of 30 kg/m2 or 
greater (obes ity) or 27 to 29.9 kg/m2 (overweight , with additional health risks ). The dose of 
tirzepatide has been defined for adult s with obesity or  overweight  and T2DM patients , but data 
are lacking in pediatric participants  with obesity . 
Study I8F-MC-GPHV ( GPHV ) will assess safety, tolerability , and PK  after 8 weeks of treatment 
with tirzepatide administered via the SC route in participants  (age 6 to 11 years) with obesity 
partitioned  according to weight (lower body weight <50kg; higher body weight ≥50 kg).  
2.2. Background   
Pediatric Obesity  
The p revalence of obesity in the US has been captured as a part of the N ational Health and 
Nutrition Examination Survey (NHANES ). The nationally representative  data clearly  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
19 demonstrate that childhood and adolescent obesity continue to be a significant concern (Skinner 
et al. 2018).  
In the US, the prevalence of obesity among pediatric patients aged [ADDRESS_708733] among adolescents aged 12 to 19 years (Skinner et al. 
2018).  
The current treatment regimens for pediatric obesity include lifestyle modification, 
pharmaco therapy, and bariatric surgery (Styne et al. 2017). The t reatment of pediatric obesity 
emphasizes positive behavior change, including healthy food choices, reduction of physical 
inactivity, and family engagement (AAP IHCW 2015; Styne et al. 2017).  
Pediatri c obesity is a multifactorial disease requiring consideration of pubertal development, risk 
for comorbidities, psychological state, and social implications (Styne et al. 2017).  
Pediatric overweight and obesity are defined based on local or regional growth  charts for 
age- and sex -specific BMI.  In the US, World Health Organization  and Centers for Disease 
Control and Prevention  growth charts are commonly used to assess BMI.  
The pathophysiology of pediatric obesity is multifactorial; a combination of heritable  and 
environmental factors leads to an imbalance between energy intake and expenditure (Crocker 
and Yanovski 2009). However, the exact etiology of obesity in pediatric patients is not clearly 
understood. Of note, pediatric obesity due to obesity syndromes or genetic conditions is 
infrequent and accounts for approximately 7% of patients with extreme pediatric obesity (Styne 
et al. 2017).  
Comorbidities of pediatric obesity  
Pediatric obesity is associated with an increased risk of premature death and comorbi dities. The  
likelihood  of developi[INVESTIGATOR_543041] , pointing to a need to address obesity as it presents in childhood (Krebs et al. 
2007). Obesity -related comorbidities include the fo llowing  (Jastreboff et al. 2019):  
• cardiovascular disease (CVD )  
• cerebrovascular diseases   
• T2DM   
• hypertension, and  
• some cancers.  
The comorbidities associated with obesity and overweight in adults  are consistent with that of 
children with obesity  (Styne et al. 2017). Additionally, the benefits associated with weight loss in 
the pediatric population with obesity are consistent with that of adults (August et al. 2008).  
In pediatric patients, for every 10 kg/m2 increase in BMI, there is an associate d 34% increased 
risk of dyslipi[INVESTIGATOR_035], 46% higher risk of hypertension, and 25% increase in insulin concentration 
(Durkin and Desai 2017).  
The risks of CVD outcomes among children and adolescents with obesity who were without 
obesity by [CONTACT_543064] . Such risk factors of 
CVD outcomes are as follows (Juonala et al. 2011) :  
• T2DM   
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
20 • hypertension  
• elevated low -density lipoprotein cholesterol  
• reduced high -density lipoprotein cholesterol  
• elevated triglyceride levels, and  
• carotid artery atherosclerosis.  
Long -term weight loss of 5% or greater as a result of lifestyle modification is associated with 
improvement in various metabolic and CV  risk factors (Brown et al. 2016). Weight loss 
interv entions that result in significant and durable weight loss, such as that associated with 
bariatric surgery, may result in multiple benefits such as  
• reduced CV risk factors  
• reduced risk of T2DM, and  
• decreased risk of CV death and all -cause mortality (Kri tchevsky et al. 2015).   
Tirzepatide  
Weight loss induced by [CONTACT_34046] -1R agonists, while appearing to be centrally  mediated through a 
combination of hormonal inputs to satiety centers (van Bloemendaal et al. 2014), has not been 
consistently associated with changes in mental health or with potential for addiction in long -term 
studies conducted to establish CV safety in patients with diabetes (Marso et al. 2016a, 2016b; 
Gerstein et al. 2019). Tirzepatide, which is both a GLP -1R and GIP receptor  agonist, has be en 
associated with predominantly mild -to-moderate GI adverse effects similar to currently marketed 
GLP -1R agonists.  
Overall summary  on weight loss in adult participants with obesity or overweight with or 
without type 2 diabetes mellitus   
In adult participa nts with T2DM, tirzepatide 5, 10, and 15 mg demonstrated superior reductions 
from baseline in body weight at the primary endpoint visit (40 or 52 weeks) in all 5 global Phase 
3 studies compared with placebo ( that is,  the management of body weight primarily  by [CONTACT_543065]), semaglutide, and basal insulin (insulin degludec and insulin glargine).  
The SURMOUNT -[ADDRESS_708734] 150 minutes of physical activit y per week . Again , tirzepatide 5, 10, and 15 mg 
demonstrated superior reductions from baseline in bod y weight at the primary endpoint visit 
(72 weeks)  in the SURMOUNT -1 study  compared with placebo  (Jastreboff et al. 2022) . 
Treatment guidelines suggest that  patients with T2DM and obesity should target a body weight 
reduction of ≥5% (ADA 2021). Across all Phase [ADDRESS_708735] that more ambitious body weight goals were feasible for many patients.  
More information about the known and expected benefits, risks, SAEs , and reasonably 
anticipated AEs of tirzepatide is to be found in the IB. 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
21 2.3. Benefit/Risk Assessment   
The r isks of tirzepatide have been consistent with risks associated with other GLP -1 receptor  
agonists currently marketed. Potential risks include, but are not limited to, GI effects, acute 
pancreatitis (very rare), increases in heart rate,  and hypoglycemic events (GLP -[ADDRESS_708736]).  
No clinically significant safety or tolerability concerns have been identified during the clinical 
investigation of tirzepatide up to the single dose level of [ADDRESS_708737] dose of  mg tirzepatide to be administered in this study are reasonably 
anticipated to be tolerable in this group of pediatric participants  with obesity . 
Body weight is a known covariate affecting tirzepatide exposures  based on population PK 
analysis in adult patients with T2DM . It is predicted  that the exposure may be approximately 
2-fold higher in the population with weight <50  kg compared to that in adult s (weight ≥50  kg); 
therefore, a more conservative initial starting dose of  will be adopted for participants in 
the lower body weight cohort (Cohort 2). This is a mitigation approach taken to reduce the risk 
of safety and tolerabilit y issues before commencing another cohort of participants on an initial 
-mg dose (Cohort 3).  
Based on the known pharmacology of tirzepatide, participants  with obesity  may benefit from 
clinically meaningful weight reduction after 8 weeks of treatment. Po tential risks, such as GI 
effects, acute pancreatitis, increases in heart rate, and hypoglycemic events , are consistent with 
the risks associated with currently available long -acting GLP -1R agonists  in adults . These risks 
are clinically detectable  and manageable and will be monitored throughout  the study.  
A juvenile toxicology study in rats was conducted to assess potential effects on growth and 
development to support pediatric development.  Rats in the study were dosed twice weekly from 
Postnatal Days 2 1 to 84, which roughly corresponds to early human pediatric (2 years of age) 
through late adolescence based on overall central nervous system and reproductive development 
across species (Rodier 1980; Bayer et al. 1993; Rice and Barone Jr 2000; Beck et al. 2006) and 
overlaps ages utilized in the general toxicology studies. Standard behavioral, reproductive, and 
pathology assessments, as well as the careful monitoring of body weight and developmental 
markers of sexual maturation (vaginal patency and balanopre putial separation), were included as 
endpoints. Consistent with adult rats, effects in juvenile rats were limited to pharmacological 
effects on body weight and food consumption and effects secondary to the pharmacology. These 
data indicate that tirzepatide  does not have unique toxicities in juvenile animals and has an 
acceptable nonclinical safety profile to support pediatric clinical trials.  
For females, use Tanner staging by [CONTACT_117145], history or occurrence of menarche , and/or 
menses to aid in the det ection of a child who is no longer Tanner 1 and may be further evaluated 
for childbearing potential.  
More information about the known and expected benefits, risks, SAEs , and reasonably 
anticipated AEs of tirzepatide is to be found in the IB . 
Approved on 16 Nov 2023 GMT
CCI
CCI
CCI
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
22 3. Objectives  and Endpoints   
Objectives  Endpoints  
Primary  
 To evaluate tirzepatide safety and 
tolerability following the SC injections of 
tirzepatide in pediatric participants  with 
obesity   
 Number  of treatment -emergent adverse events 
and serious adverse events  
 
Secondary  
 To evaluate the PK profile of tirzepatide 
following SC injections in pediatric 
participants  with obesity   
 Tirzepatide area under the concentration versus 
time curve (AUC 0-tau), ma ximum concentration 
(Cmax) from population PK model  
Abbreviations : ; PK = pharmacokinetic s; SC = subcutaneous . 
Approved on 16 Nov 2023 GMT
CCI
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708738] diab etes mellitus . Potential 
pediatric participants will be screened to assess their eligibility to enter the study within 28 days 
prior to Day 1.  Participants enrolled will be partitioned  as follows:   
 Cohort 1: Higher weight cohort – screening  body weight ≥50  kg 
 Cohort 2: Lower weight cohort  – screening  body weight <50 kg , and  
 Cohort 3: Screening body weight between 40 to 60 kg, inclusive .  
The s chematic of the study is shown in  Figure GPHV. 1.1. Initially,  participants  
are planned to be enrolled into the higher body weight (Cohort 1).  Participants will be 
randomized on Day 1 to tirzepatide or placebo (  ratio) afte r the confirmation of eligibility.  
Placebo is included as the control in a blinded manner for investigator, site staff, and participants 
to allow an unbiased assessment of the safety and tolerability data generated, which will allow a 
more robust compariso n between tirzepatide and placebo.  In-clinic outpatient visits are planned 
as detailed in the SoA. 
Safety and tolerability data will be reviewed by [CONTACT_543066], CRP /CRS , and 
blinded investigator . Decisions for commencing dosing in Cohort 2 (lower body weight 
participants) will be made based on the following:   
 the completion of at least [ADDRESS_708739]  participants in Cohort 1 , and  
 the review of safety/tolerability data through Day 36, including safety clinical laboratory .  
Likewise, the dosing of Cohort 3 participants ( body weight 40 to 60 kg inclusive ) will proceed 
only after the satisfactory revie w of safety and tolerability data from at least  participants who 
received at least [ADDRESS_708740] 1 week are acceptable in the  sentinel participants, as clinically 
assessed by [CONTACT_093], the remainder of the participants in Cohort 3 (  tirzepatide and  
placebo) in the [ADDRESS_708741]  4 weeks  but 
up to 6 weeks  for participants who discontinued prematurely.   
Starting at Visit 2 ( baseline  visit) , all participants will be offered  intensive behavioral therapy 
(IBT)  session s (Section 5.3.1 ) which will continue through the study period  and until  the final 
follow up.  
4.2. Scientific Rationale for Study Design   
This study is designed to assess the safety, tolerability , and PK profile of tirzepatide administered 
SC in participants  aged 6 to 11 years with obesity .  
The dose justification for tirzepatide is provide d in Section 4.3. 
Approved on 16 Nov 2023 GMT
CCI
CCI
C
C
I
C
C
I
C
C
I
C
C
I
C
C
I
CCI
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708742] 
comparison of safety, tolerability, and PD data.  
Sentinel dosing design will be used in   Cohort 3 because this cohort has a higher starting dose 
compared to  Cohort 2 , while allowing participants with body weight be low 50 kg . Cohort  1 will 
include  participants ≥ 50 kg at a starting dose of  mg . Cohort 3 will include participants in the 
range of 40 to 60 kg at a starting dose of  mg . Hence, sentinel dosing  will be used in  
participants in the body weight range of 40 to 50 kg  in Cohort 3 , as this weight range is not 
included in Cohort 1.  Sentinel dosing design is included  to assess  the tolerability or safety 
profile s due to increased starting dose in participants with obesity  receiving  tirzepatide . 
4.3. Justification for Dose   
A starting dose of  mg accompanied by [CONTACT_543067] 4 weeks (up 
to a maxim um dose of 15 mg) was shown safe and well tolerated in adults with T2DM . The body 
weight of the pediatric participants  in the higher body weight cohort (Cohort 1) in this study will 
overlap with the weight of adults studied in the T2DM program (weight around or higher than 
50 kg). Thus, a starting dose of  mg for 4 weeks, followed by  [CONTACT_543068] 4 weeks , is planned for 
this pediatric population with body weight more than or equal to 50  kg.  
The exposure in pediatric participants  with we ight <50  kg is anticipated to be up to 2 -fold higher  
than the exposure  in adults  (weight range in Phase 3 studies  in adults with T2DM:  43.1 to 
227 kg), given that body weight was identified as a covariate on tirzepatide exposures in adults. 
Thus , a lower starting dose of  mg in this pediatric population with weight below 50  kg will 
be evaluated for tolerability and safety  in Cohort 2 . If the starting dose of  mg is 
well-tolerated, a starting dose of  mg will also be tested in Cohort 3 w ithin a narrow er weight 
range (40 to 60 kg, inclusive) . 
4.4. End of Study  Definition   
The end of the study is defined as the date of the last visit of the last participant in the study  or 
last scheduled procedure shown in the SoA for the last participant.  
A participant is considered to have completed the study if the participant  has completed the last 
scheduled procedure shown in the SoA. 
Approved on 16 Nov 2023 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
25 5. Study Population   
The e ligibility of participants for the study will be largely based on the results of medical history, 
physical examination, vital signs, clinical laboratory tests , and 12 -lead ECG .  
The nature of any conditio ns present at the time of the physical examination and any preexisting 
conditions will be documented.  
Screening may occur up to 28 days prior to Day 1. If the investigator decides not to administer 
the dose to a participant or not to enroll a participant o n a particular day, the participant’s visit 
may be rescheduled, and any assessments or procedures performed up to that point may be 
repeated to confirm their eligibility.  
The p rospective approval of protocol deviations to recruitment and enrollment criter ia, also 
known as protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria   
Participants are eligible for inclusion in the study if  they meet all of the following criteria at 
screening:  
Participant Characteristics  
1. Are male and fe male participants with obesity  determined  by [CONTACT_177964]  
a. between the ages of [ADDRESS_708743] BMI ≥ the 95th percentile for age and sex  
2. Have a screening body weight of  
▪ Participants to be enrolled into Cohort 1: ≥50 kg  
▪ Participants to be enrolled into Cohort 2: <50 kg  
▪ Participants to be enrolled into Cohort 3: Between [ADDRESS_708744] f ailed to achieve adequate weight loss through lifestyle modification 
in the investigator ’s opi[INVESTIGATOR_1649]  
4. Have adequate immunization according to local / national requirement as 
assessed by [CONTACT_093]  
5. Not be sexually active  and remain so throughout the duration of the study  
6. Have saf ety laboratory test results within normal reference range or with 
abnormalities deemed clinically insignificant by [CONTACT_093]  
7. Have venous access sufficient to allow for blood sampling as per the 
protocol  
8. Female  participants with obesity  only: Determi ned as prepubertal Tanner 
Stage  1. See Appendix 7 (Section 10.7) for further details on Tanner 
Staging.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
26 Informed Consent  
9. Both child and parent or legal guardian are reliable and willing to make 
themselves available for the duration of the study and are willing to follow 
study procedures  
10. Both child and parent or legal guardian are willing and able to commit to the 
inpatient stays and procedures per s tudy requirement  
11. Both the child and a parent or legal guardian are able to understand and fully 
participate in the activities of the clinical trial and sign their assent and 
consent, respectively  
5.2. Exclusion Criteria   
Participants will be excluded from study enrollment if they meet any of the following criteria at 
screening:  
Medical Conditions - General  
12. A self -reported (or by [CONTACT_7078](s)/legally acceptable representative where 
applicab le) change in body weight above 5 kg (11 lbs) within [ADDRESS_708745] a history or current CV (for example, acute myocardial infarction, 
congestive heart failure, unstable angina, uncontrolled hypertension 
[systolic blood pressure ≥ 160 mmHg and diastolic blood pressure ≥ 100 
mmHg], cerebrovascular accident [including transient ischemic attack], 
venous thromboembolis m, and so on) , respi[INVESTIGATOR_696], hepatic, renal, GI, 
endocrine, hematological (including history of th rombocytopenia), or 
neurological disorders capable of significantly altering the absorption, 
metabolism, or elimination of drugs; constituting a risk when taking the IP; 
or may interfere with the interpretation of data  
14. Have obesity induced by [CONTACT_543069] (for example, 
Cushing syndrome) or diagnosed monogenetic or syndromic forms of 
obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi 
Syndrome)  
15. Have acute or chronic pancreatitis or a history of acute idiopathic 
pancreat itis; or have other GI disorders (for example, relevant esophageal 
reflux or gall bladder disease) that could be aggravated by [CONTACT_34046] -1 analogs; 
participants who had cholecystolithiasis (gall stones) or cholecystectomy 
(removal of gall bladder) in the past, w ith no long -term complications, are 
eligible for participation  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708746] a known clinically significant gastric emptying abnormality ( for 
example,  gastric outlet obstruction), have undergone weight loss surgery 
such as gastric by[CONTACT_6476] (bariatric) surgery or rest rictive bariatric surgery ( for 
example,  Lap-Band ®), or have endoscopic or device -based therapy for 
obesity or have had device removal within the last 6  months (for example, 
mucosal ablation, gastric artery embolization, intragastric balloon , and 
duodenal -jejunal by[CONTACT_17991])  
17. Have a personal or family history of medullary thyroid carcinoma , have 
multiple endocrine neoplasia syndrome type 2 , or calcitonin ≥20  pg/mL at 
screening  
18. Have confirmed type 1  or type 2 diabetes  mellitus  or a history of 
ketoacidosis, or hyperosmolar state/coma  
19. Have findings in the [ADDRESS_708747] been in remission from a 
clinically significant malignancy (other than basal or squamous cell skin 
cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for 
<[ADDRESS_708748] evidence of hepatitis B or positive hepatitis B surface antigen or 
evidence of HCV  or hepatitis C antibody with confirmed presence of HCV  
RNA  at screening (a positive HCV antibody at screening will need an 
additional HCV RNA assay  - detectable HCV RNA means a participant will 
meet exclusion criteria)  
 Participants with a previous diagnosis of HCV who have been 
treated with antiviral therapy and achie ved a sustained virological 
response may be eligible for inclusion in the study, provided they 
have no detectable HCV RNA on the screening HCV polymerase 
chain reaction test. A sustained virological response is defined as 
an undetectable HCV RNA level 24 w eeks after the completion of 
a full, documented course of an approved antiviral therapy for 
HCV.  
 Participants who have spontaneously cleared HCV infection, 
defined as ( a) a positive HCV antibody test and ( b) a negative 
HCV RNA test, with no history of anti -HCV treatment, may be 
eligible for inclusion in the study, provided they have no detectable 
HCV RNA on screening for this study.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708749] or ALT >2.0× the ULN or TBL >1.5  × ULN (except for 
participants with Gilbert’s syndrome, which can be enrolled with TBL 
<2.0× ULN), or alkaline phosphatase (ALP) >1.5× ULN  
 Participants with nonalcoholic fatty liver disease are allowed to 
participate . 
24. Have any lifetime history of a suicide attempt  
25. Have had a blood transfusion or severe blood loss within the last [ADDRESS_708750] a hemoglobin value <11 g/dL (males) or <10 g/dL 
(females) or any other condition known to interfere with safety laboratory 
measurements  
26. Have a history of atopy or clin ically significant multiple or severe drug 
allergies, or severe posttreatment hypersensitivity reactions (including, but 
not limited to, erythema multiforme major, linear immunoglobulin A 
dermatosis, toxic epi[INVESTIGATOR_194], or exfoliative dermatitis)  
27. Impaired renal eGFR of <60  mL/min/1.[ADDRESS_708751] may be performed in case of an initial borderline eGFR result of 
<60 mL/min/1.[ADDRESS_708752] an accompanying parent or legal guardian who is unable or unwilling 
to stop alcohol or nicotine consumption from admission to the CRU and 
until discharge from the study or completion of all study procedures at the 
CRU  
Prior/Co ncomitant Therapy - General  
29. Have been treated with prescription drugs that promote weight loss ( for 
example,  sibutramine, mazindol, phentermine, naltrexone  or bupropi[INVESTIGATOR_2394], or 
liraglutide) or similar other weight-loss medications, including over -the-
counter m edications ( for example,  Alli ®) within [ADDRESS_708753] received chronic (lasting >14 consecutive days) systemic 
glucocorticoid therapy (excluding topi[INVESTIGATOR_2855], intra -articular, and inhaled 
preparations) within [ADDRESS_708754] received treatment with a drug that has not received regulatory 
approval for any indication within 30 days or 5  half-lives (whichever is 
longer) of screening  
33. Have pre viously completed or withdrawn from this study  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708755] 
parent or legal guardian who are deemed unsuita ble by [CONTACT_543070] . 
5.3. Lifestyle Considerations   
Throughout the study, participant s may undergo medical assessments and review of compliance 
with requirements before continuing in the study.  
5.3.1.  Intensive Behavioral Therapy (IBT) for Chronic Weight Management in 
Children 6 -11 Years Old   
All participants will be offered  IBT that meets current practice guidelines and recommendations 
(APA 2018; Barlow 2007; USPSTF 2017). The IBT will include individual and family -based 
sessions for all study participants, including participants assigned to placebo (Farris et al. 2011; 
Mayr  et al. 2020). After completing the follow -up visit, participants may have the option to 
receive [ADDRESS_708756] samples are taken. 
During the inpatient stay, participants may not consume any food other than that provided by [CONTACT_27470], although water may be consumed freely . 
5.3.3.  Substance Use: Caffeine, Alcohol, and Tobacco   
No alcohol and nicotine use will be permitted for participants  and accompanying  parent or legal 
guardian resident in the CRU . 
Participant s will be allowed to maintain their regular caffeine consumption throughout the study 
period (except during specific fa sting time periods).  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
30 5.3.4.  Activity  and Vaccinations   
Intense physical activity should be avoided 48 hours prior to tirzepatide dosing on Day  1 until 
the completion of all study procedu res. 
Participants should continue on their current vaccination and immunization schedule as per local 
or national requirement . 
5.4. Screen Failures   
A screen failure occurs  when a participant  who consent s to participate in the clinical study  is not 
subsequently enrolled  in the study .  
Screening tests such as clinical laboratory tests and vital signs/ECGs may be repeated at the 
discretion of the investigator . Individuals who do not m eet the criteria for participation in this 
study (screen failure) may not be re -screened. Participant  numbers are assigned earliest on Day 1 
to ensure that only eligible participant s enter the study.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
31 6. Study Intervention (s) and Concomitant Therapy   
Study intervention is defined as any study drug inter vention, investigational intervention(s), 
marketed product(s), placebo, or medical device(s) intended to be administered to or used by a 
study participant according to the study protocol.   
 
6.1. Study Intervention(s) Administered   
Participants will receive the SC doses of tirzepatide or placebo SC weekly . Matching placebo 
and tirzepatide  mg and  mg in prefilled syringes will be provided.  For participants in 
Cohort  [ADDRESS_708757] to be in -clinic ( that 
is, remote visits will not be permitted) for Visits 2 to 5 for safety as well as for treatment 
preparation reasons.   
Participants and legal guardian s will receive a paper diary for the collection of study intervention 
details d uring remote visits . Paper diaries should be returned  at the next site visit.   
Table GPHV. 6.1 shows the treatments administered.   
 
Table GPHV. 6.1. Treatments Administered   
Intervention  
name   [CONTACT_543109](s)    mg  m L  
 mg  m L  
 mg/  m L  Injections with the volume matching the 
investigational drug at each dose level  
Route of 
administration   Subcutaneous   Subcutaneous  
 
Packaging and labeling  
Study intervention s will be supplie d by [CONTACT_543071]. Study interventions  will be labeled as appropriate for country 
requirements . 
6.1.1.  Administration Details   
When performed during  on-site visits, study drug administration for each participant should be 
carried out by a limited number of site personnel for consistency . The participant (or parent or 
legal guardian) will be permitted to perform self -administration on other dosing occa sions after 
being trained by [CONTACT_543072] 16 Nov 2023 GMT
CCI
CCI
CCI
CCI
CCI
C
C
I
CCI
CCI
CCI
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
32 the sponsor. On occasions where the visit is performed remotely, the visiting nurse will be 
permitted to administer the scheduled dose.  
All injections will be administered into the SC tissue of the abdominal wall, with  injection sites 
alternated weekly between 4 sites, that is, right and left upper quadrants and right and left lower 
quadrants.  Dosing will ideally occur at approximately the sam e time of day in all dose cohorts.  
The actual time of dosing will be recorded in the patient’s eCRF. 
Participant s will receive tirzepatide or placebo SC starting on Day 1.  
The investigator or designee is responsible for  
 explaining the correct use of the study intervention  to the site personnel  
 verifying that instructions are followed properly  
 maintaining the accurate records of study intervention  dispensing and collection , and  
 returning all unused medication to the sponsor  or its designee at the end of t he study . 
Note:  In some cases, sites may destroy the material if, during the investigative site selection, the 
evaluator has verified and documented that the site has appropriate facilities and written 
procedures to dispose of clinical materials.  
6.1.2.  Medical Devices   
The combination products provided for use in the study are the tirzepatide prefilled syringe  and 
placebo prefilled syringe . 
Product complaints  (including malfunction, use  error , and inadequate labeling) shall be 
documented and reported by [CONTACT_543073] (see Section 10.3.3 ). 
6.2. Preparation , Handling , Storage , and Accountability   
The investigator or designee must confirm that appropriate storage conditions have been 
maintained during transit for all study intervention received and any discrepancies are reported 
and resolved before the use of the study intervention.  
Only participants enrolled in the study may receive study intervention . Only author ized study 
personnel  may supply , prepare,  or administer study intervention. All study intervention must be 
stored in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with acces s limited to the investigator and 
authorized  study personnel . 
The investigator  or authorized study personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance ( that is,  receipt, reconciliation, and final 
disposit ion records).  
All used or unused study drugs may only be destroyed by [CONTACT_543074] .  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
33 6.3. Measures to Minimize Bias: Randomization and Blinding   
This is a participant - and investigator -blinded study. To preserve the blinding of the study for 
tirzepatide and placebo, all study site personnel, except staff who prepare  and dispense  study 
intervention, will be blinded to treatment allocation . 
All participants will be centrally assigned to randomized study intervention using an Interactive 
Web Response System . Before the study is initiated, the log -in information and directio ns for the 
Interactive Web Response System  will be provided to each site.  
Study intervention will be dispensed at the study visits summarized in SoA.  
Returned study intervention should not be re -dispensed to participants.  
If a participant’s study treatmen t assignment is unblinded, the participant must be discontinued 
from the study, unless the investigator obtains specific approval from a sponsor  CP or CRP for 
the study participant to continue in the study. During the study, emergency unblinding should 
occur only by [CONTACT_543075]’s emergency code.  
In case of an emergency, the investigator has the sole responsibility for determining if the 
unblinding of a participant’s treatment assignment is warranted for the medical management of 
the eve nt. The participant’s safety must always be the first consideration in making such a 
determination. Where feasible and when timing of the emergent situation permits, the 
investigator should attempt to contact [CONTACT_543076] a p articipant’s 
treatment assignment. If the investigator decides that unblinding is warranted, it is the 
responsibility of the investigator to promptly document the decision and rationale and notify the 
sponsor  as soon as possible.  
Upon the completion of th e study, all codes must be returned to the sponsor  or its designee.  
6.4. Study Intervention Compliance   
When participants are dosed during outpatient visits at the CRU, study intervention will be  
administered under medical supervision by [CONTACT_1719]. The dose of study 
intervention and study participant identification will be confirmed prior to the time of dosing.  
The date and time of each dose administered will  be recorded in source documents and will be 
provided to the sponsor as requested.  
Self-administration by a participant or parent or legal guardian is permitted after the investigator 
has assessed them as being adequately trained. When administ ered at home , dosing information 
will be recorded in study dosing records provided by [CONTACT_543077] . Compliance will be further a ssessed by [CONTACT_543078].  
A record of the number of study intervention prefilled syringes  dispensed to and taken by [CONTACT_543079] e records. 
Intervention start and stop dates, including dates for intervention delays , will also be recorded in  
the CRF.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
34 6.5. Dose Modification   
Dose modification other than that defin ed per protocol is not permitted in this study.   
In certain situations,  after randomization, for example, if GI tolerability AEs occur, the 
investigator may need to temporarily interrupt treatment. Investigators should preferably consult 
with and notify th e sponsor CP/CRP , if treatment needs to be interrupted. Every effort should be 
made by [CONTACT_543080], as soon as it is assessed as safe to do so. The participant  should resume 
study treatment administration at the scheduled dose level per protocol.   
If any of the following scenarios occur, dosing at the current level and further dosing will be 
stopped for the participant who will be discontinued:   
1. The SAE is consi dered at least possibly related to the study intervention .  
2. A severe non -serious AE occurs and  is considered at least possibly related to the study 
intervention occurring in the participant.   
3. The participant experiences intolerable GI events that require f urther dose interruptions , 
and the investigator or designee determines that it  is unsafe to resume continued 
treatment .  
If any of the following scenarios occur, an additional safety review will be initiated and new 
enrollment will be paused until the safety review is complete :  
1. One or more participants in the cohort on active drug experience SAE considered to be 
related to tirzepatide . 
2. One or more participants on active drug experience 2 clinically significant severe AEs 
considered to be related to tir zepatide . 
3. Two or more participants in the cohort experience   
a. drug-related GI effects ( for example,  emesis and diarrhea) assessed to be severe 
treatment -emergent AEs causing significant distress or requiring urgent medical 
interventions beyond routine sympt omatic treatment , and  
b. symptomatic hypoglycemic epi[INVESTIGATOR_543042] <3. 0 mmol/L 
(54 mg/dL ).  
6.5.1.  Data Review during the Study   
Data will be analyzed while the trial is ongoing. An assessment committee will not be formed.  
Safety data will be reviewed by [CONTACT_429212] a regular basis while participants are enrolled in the 
study.   
Two safety data review s are planned to occur during the Study GPHV.  Such an interim safety 
review will not be considered as formal interim analyses.  This review will be used to support 
dose decisions for subsequent cohorts to be enrolled.  The interim data reviews will include  the 
following :  
 Cohort [ADDRESS_708758] 5 weeks of treatment , and   
 Cohort [ADDRESS_708759] participants with obesity in Cohort 2 who received and 
Approved on 16 Nov 2023 GMT
CCI
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708760] 5 weeks of treatment and all available safety and tolerability data from 
Cohort 1  participants.   
At the time of safety reviews , any available PK data may also be reviewed  by [CONTACT_3211] . 
6.6. Continued Access to Study Intervention after the End of the Study   
Not applicable.  
6.7. Treatment of Overdose   
For this study, any dose of study intervention  greater than  mg will be considered an overdose  
in Cohorts 1 and 3 . Likewise for Cohort 2, doses above  mg will be con sidered an overdose.  
In the event of an overdose, the investigator should  
● contact [CONTACT_10990]  
● evaluate the participant to determine, in consultation with the medical monitor, if 
additional tests and  treatment will be required  
● closely monitor the participant for any AE/SAE and laboratory abnormalities until 
the participant  is clinically stable or recovering  
● obtain a n unscheduled  plasma sample for PK analysis  if requested by [CONTACT_35011] (determined on a case -by-case basis) , and  
● document the quantity of the excess dose in the CRF . 
6.8. Concomitant Therapy   
Prior to therapeutic intervention, an investigator must review the study participant’s vaccine 
record to evaluate the risk of under -immunization to the pediatric study participant.  
In general, concomitant medication should be avoided. If the need for concomitant medication 
arises (for example, to treat an AE), inclusion or continuation of the participant  may be at the 
discretion of the investigator, preferably after consultation with  a sponsor CP or CRP /CRS  or 
designee. Any medication used during the course of the study must be documented.  
All participant s on stable concomitant medication at the time of study entry, other than those that 
are prohibited, should continue their usual  dose throughout the study  unless deemed clinically 
necessary .  
To mitigate potential GI symptoms due to tirzepatide and manage participant s with poorly 
tolerated GI AEs, the investigator  
 should a dvise the child to eat slowly or offer smaller meals, for example, splitting 3  daily 
meals into 4 or more smaller meals, and to stop eating when they feel full , and  
 may prescribe symptomatic medication (for example, approved anti -emetic or 
antidiarrheal medication for children) . 
Approved on 16 Nov 2023 GMT
C
C
I
CCI
CONFIDENTIAL  I8F-MC-GPHV (e) 
36 Any medication or vaccine (includi ng over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements ) that the participant is receiving at the time of enrollment or receives 
during the study must be recorded along with  
 reason for use  
 dates of administration including start and end dates , and  
 dosage information including dose and frequency for concomitant therapy 
of special interest . 
The medical monitor should be contact[CONTACT_63193].  
Participants must abstain from starti ng any new prescription or nonprescription drugs after 
screening unless, in the opi[INVESTIGATOR_543043]/CRS, the medication is  assessed as  clinically necessary or is deemed unlikely  to interfere 
with the study outcome . 
If acetaminophen  treatment is needed for pain management, the maximal allowed dose will be 
the amount as stipulated in the package insert for the body weight and age of the participant.  
Other concomitant medication may  be considered on a case -by-case basis by [CONTACT_543081] . 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
37 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal   
The d iscontinuation of specific sites or of the study as a whole is handled as a part of Appendix 1  
(Section 10.1). 
When  necessary , a participant  may be permanently discontinue d from  study intervention . If so, 
the pa rticipant , must complete early discontinuation  procedures  as shown in the SoA .  
7.1. Discontin uation of Study Intervention   
A participant may not receive  study intervention if  
 the participant  (females only)  exhibits signs and symptoms of puberty , and  
 in the opi[INVESTIGATOR_871], the participant should not receive  study 
intervention for  safety reasons . 
If the investigator, after consultation with the sponsor -designated medical monitor, determines 
that a systemic hypersensitivity reaction has occur red related to study intervention  
administration, the participant should be permanently discontinued from the intervention , and the 
sponsor’s designated medical monitor should be notified. If the investigator is uncertain about 
whether a systemic hypersens itivity reaction has occurred and whether discontinuation of study 
intervention is warranted, the investigator may consult the sponsor.  
7.2. Participant Discontinuation/ Withdrawal from the Study   
Discontinuation is expected to be uncommon.  
A participant  may withdraw from the study  
 at any time at the participant’s  own request  
 at the request of the participant’s  designee (for example, parents or legal 
guardian)  
 at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons  
 if enrolled in any other clinical study involving an IP, or enrolled in any other 
type of medical research judged not to be scientifically or medically 
compatible with this study , and 
 if the participant , for any reason, requires treatment with a therapeutic agent 
that is prohibited by [CONTACT_543082] . In this case , discontinuation 
from the stu dy occurs prior to introduction of the new agent . 
At the time of discontinuing from the study, if possible,  the participant will complete  procedures 
for an early discontinuation visit , as shown in the SoA. If the participant has not already 
discontinued th e study intervention, the participant will be permanently discontinued from the 
study intervention at the time of the decision to discontinue the study.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708761] 
participants and their parents or legal guardian who fail to return for a scheduled visit or were 
otherwise unable to be followed up by [CONTACT_779].   
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708762] reasons for sc reening failure, as 
applicable .  
8.1. Efficacy Assessments   
Although this study is primarily a safety and tolerability study, weight loss is a potential benefit 
for children with obesity. Body weight will be assessed as a part of safety and also potential 
efficacy measure according to the SoA .  
8.2. Safety Assessments   
Planned time points for all safety assessments are provided in the SoA.  
8.2.1.  Physical Examinations   
A complete physical examination will include, at a minimum, the assessments of CV, 
respi[INVESTIGATOR_696], GI and neurological  systems . Height and weight will also be measured and recorded.  
A brief physical examination will include, at a minimum, assessments of the skin, lungs, CV 
system, and abdomen (liver and spleen).  
Investigators should pay special attention to clinical signs related to signs and symptoms of 
puberty . 
8.2.2.  Body Weight, Body Mass Index, Height, and Waist  Circumference   
Body weight, height, and waist circumference will be measured at prespecified time points. Each 
participant’s weight, height, and waist circumference must be measured according to 
standardized guidelines (Section  10.9 [Appendix 9]). BMI  will be computed from the 
participant’s weight and height . 
8.2.3.  Assessment of Pubertal Status  - Tanner Staging   
Female p articipants’ pubertal status  will be assessed using  Tanner Staging performed at 
screening  and other scheduled time points per protocol  (see also Section  10.7 [Appendix 7]  for 
Tanner Stages).  This study will only include female participants that are at Tanner Stage 1.   
8.2.4.  Vital Signs   
For each  participant , vital signs measurements should be conducted according to the SoA 
(Section  1.3).  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708763] 3 minutes. If the participant feels una ble to stand, supi[INVESTIGATOR_80492].  
8.2.5.  Electrocardiograms   
Single  12-lead ECG will be obtained as outlined in the SoA (see Section  1.3). ECGs may be 
obtained at additional times, when deemed clinically necessary.  
8.2.6.  Clinical Safety Laboratory Tests   
See Appendix [ADDRESS_708764] be 
retained with source documents unless a Source Documen t Agreement or comparable document 
cites an electronic location that accommodates the expected retention duration. Clinically 
significant  abnormal laboratory findings are those which are not associated with the underlying 
disease, unless judged by [CONTACT_19448]'s 
condition.  
All laboratory tests with values considered clinically signific antly abnormal during participation 
in the study should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by [CONTACT_093].  
 If such values do not return to normal/baseline within a period of tim e judged 
reasonable by [CONTACT_093], the etiology should be identified and the sponsor must 
be notified.  
 All protocol -required laboratory assessments, as defined in Appendix 2, must be 
conducted in accordance with the SoA , standard collection requireme nts, and 
laboratory manual . 
If laboratory values from non -protocol specified laboratory assessments performed at an 
investigator -designated local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_093] ( for example , SAE or AE), then  report the 
information as an AE .  
8.2.7.  Safety Monitoring   
Hepatic Safety   
Close hepatic monitoring a 
Laboratory tests (Appendix 2), including ALT, AST, ALP, TBL, direct bilirubin , gamma -
glutamyl transferase , and creatine kinase , should be repeated within 48 to 72 hours to confirm 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
41 the abnormality and to determine if it is increasing or decreasing, if one or more of following 
conditions occur:  
If a participant with baseline results 
of...  Develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with Gilbert’s 
syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for patients with Gilbert’s 
syndrome)  
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; TBL = total bilirubin; ULN = 
upper limit of normal.  
a All ULN values should be age -adjusted (AAULN) . 
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by [CONTACT_543083] -designated medical monitor. At a minimum, this e valuation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses (for example, 
heart failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including over -the-counter), herbal and dietary supplements, history of alcohol 
drinking , and other substance abuse.  
Initially, the monitoring of symptoms and hepatic biochemical tests should be done at a 
frequency of 1 to 3 times weekly, based on the participant’s cli nical condition and hepatic 
biochemical tests. Subsequently, the frequency of monitoring may be lowered to once every 1 to 
2 weeks, if the participant’s clinical condition and lab results stabilize. The m onitoring of ALT, 
AST, ALP, and TBL should continue until levels normalize or return to approximate baseline 
levels. Special care should be taken to minimize the volume of blood taken during hepatic 
monitoring.  
Comprehensive hepatic evaluation a 
A comprehensive evaluation should be performed to search for p ossible causes of liver injury if 
one or more of the following conditions occur:  
  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
42 If a participant with baseline 
results of...  Develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs/symptoms ,b or  
ALT or AST ≥5x ULN 
ALP <1.5x ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with Gilbert’s syndrome)  
  ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs/symptoms ,b or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for patients with Gilbert’s syndrome)  
Abbreviations: ALT = alanine aminotransferase; AST =  aspartate aminotransferase; TBL = total bilirubin; ULN = 
upper limit of normal.  
a All ULN values should be age -adjusted (AAULN) . 
b Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, 
and eosinophilia >5%.  
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as wel l as tests for PT -INR and direct bilirubin, if total bilirubin was 
elevated.  
Based on the participant’s age, medical history , and initial results, further testing should be 
considered in consultation with the Sponsor -designated medical monitor, including t ests for viral 
hepatitis A, B, C, E , as well as autoimmune hepatitis; or an abdominal imaging study (for 
example, ultrasound, MRI, or CT scan ). Consider additional tests, based on the medical history 
and clinical pi[INVESTIGATOR_1103], including tests for hepatitis D vi rus, cytomegalovirus, Epstein -Barr virus , 
acetaminophen levels, acetaminophen protein adducts, urine toxicology screen, Wilson’s disease, 
blood alcohol levels, urinary ethyl glucuronide, and blood phosphatidylethanol. Special care 
should be taken to priori tize more pertinent blood tests and minimize the volume of blood taken 
during hepatic evaluation. Based on the circumstances and the investigator’s assessme nt of the 
participant’s clinical condition, the investigator should consider referring the participa nt for a 
pediatric hepatologist or gastroenterologist consultation, magnetic resonance 
cholangiopancreatograph y, endoscopic retrograde cholangiopancreatography, cardiac  
echocardiogram, or a liver biopsy as deemed appropriate for the clinical condition and 
participant’s age.  
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver tests during the study  
Additional hepatic safety data c ollection in hepatic safety CRF s should be performed in study 
participants who meet 1 or more of the following 5 conditions:   
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
43 1. Elevation of serum ALT to ≥5x ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5x ULN) . 
 In participants with baseline ALT ≥1.5x ULN, the threshold is ALT ≥3x baseline 
on 2 or more consecutive tests . 
2. Elevated TBL to ≥2x ULN (if baseline TBL <1.5x ULN) (except for cases of known 
Gilbert ’s syndrome) . 
 In participants with baseline TBL ≥1.5x ULN, the threshold should be TBL ≥2x 
baseline . 
3. Elevation of serum ALP to ≥2x ULN on 2 or more consecutive blood tests (if baseline 
ALP <1.5x ULN) . 
 In participants with baseline ALP ≥1.5x ULN, the threshold is ALP ≥2x baseline 
on 2 or more consecutive blood tests . 
4. Hepatic event considered to be a n SAE . 
5. Discontinuation of study drug due to a hepatic event .  
Note:  The interval between the [ADDRESS_708765] in all studies with tirzepatide , including this study. The 
diagnosis of acute pancreatitis requires 2 of the following 3 features (Banks 2006 ; Koizumi  
2006):  
 abdominal pain, characteristic of acute pancreatitis (that is, epi[INVESTIGATOR_543044], often associated with nausea and vomiting)  
 serum amylase (total, pancreatic, or both) or lipase ≥3X ULN , and  
 characteristic findings of acute pancreatitis on CT scan or MRI . 
If acute pancreatitis is suspecte d, the investigator should  
 obtain appropriate laboratory tests, including pancreatic amylase (p -amylase) and 
lipase  
 perform imaging studies, such as abdominal CT scan with or without contrast or 
abdominal MRI , and  
 evaluate for the possible causes of acute pancreatitis, including alcohol use, 
gallstone/gall bladder disease, hypertriglyceridemia, and concomitant medications.  
Discontinuation for acute pancreatitis  
If acute pancreatitis is diagnosed, the participant must discontinue the use of IPs.  
Asymptomati c elevation of serum amylase and lipase  
The s erial measures of pancreatic enzymes have limited clinical value for predicting epi[INVESTIGATOR_543045] (Nauck et al. 2016; Steinberg et al. 2017a, 
2017b). Therefore, further  diagnostic follow -up of cases of the asymptomatic elevation of 
pancreatic enzymes (lipase or p -amylase ≥3X ULN) is not mandated but may be performed 
based on the investigator’s clinical judgment and assessment of the participant’s overall clinical 
condition.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708766] Complaints   
The definitions of the following events can be found in Appendix 3:  
 AEs 
 SAEs , and  
 PCs. 
These events will be reported by [CONTACT_543084](s) , or the participant’s legally 
authorized representative.  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definitions and remain responsible for following up events that 
are serious, considered related  to the study intervention or study procedures, or that caused the 
participant to discontinue the study  (see Section 7). 
Care will be taken not to i ntroduce bias when detecting events. Open -ended and non -leading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow each participant at 
subsequent visits  or contacts. All adverse events  will be followed until resolution, stabilization, 
the event is otherwise explained, or the participant is lost to follow -up (as defined in Section 
7.3). For PCs, the investigator is responsible for ensuring that follow -up includes any 
supplemental investigations as indicated to elucidate the nature or causality. Further information 
on follow -up pro cedures is provided in Section  10.3 (Appendix 3) .  
Investigators are responsible for monitoring the safety of participants who have entered this 
study and for alerting the sponsor  or its designee to any event that seems unusual, even if this 
event may be considered an unanticipated benefit to the participa nt. 
The investigator is responsible for the appropriate medical care of participants during the study.   
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
45 8.3.1.  Timing and Mechanism for Collecting Events   
This table describes the timing , deadlines , and mechanism for collecting events.  
Event  Collection Start  Collection 
Stop  Timing for 
Reporting to 
Sponsor or Designee  Mechanism for 
Reporting  Back -up 
Method 
of 
Reporting  
AE 
AE Signing of the ICF  
and assent as 
applicable  Participation 
in study has 
ended  As soon as possible 
upon site awareness  AE CRF  N/A 
SAE 
SAE and SAE 
updates - prior 
to the start of 
study 
intervention 
and deemed 
reasonably 
possibly 
related to study 
procedures  Signing of the ICF  
and assent as 
applicable  Start of 
intervention  Within 24 hours of 
awareness  SAE paper form  SAE 
paper 
form  
SAE  and SAE 
updates  - after 
start of study 
intervention  Start of 
intervention  Participation 
in study has 
ended  Within 24 hours of 
awareness  SAE paper form  SAE 
paper 
form  
SAE a - after 
participant’s 
study 
participation 
has ended and 
the investigator 
becomes aware  After participant’s 
study participation 
has ended  N/A Promptly  SAE paper form  N/A 
Pregnancy             
Pregnancy 
in female 
participants  After the start of 
study intervention   [ADDRESS_708767] 
injection of 
TZP Within 24 hours (see 
Section  8.3.2 )  Pregnancy paper 
form   Pregnancy 
paper 
form   
PCs 
PC associated 
with an SAE  or 
might have led 
to an SAE  Start of study 
intervention  End of study 
intervention  Within 24 hours of 
awareness  PC form  N/A 
PC not 
associated with 
an SAE  Start of study 
intervention  End of study 
intervention  Within 1 business day 
of awareness  PC form  N/A 
Updated PC 
information  - - As soon as possible 
upon site awareness  Originally 
completed PC 
form with all 
changes signed and 
dated by [CONTACT_1275]  N/A 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
46 Event  Collection Start  Collection 
Stop  Timing for 
Reporting to 
Sponsor or Designee  Mechanism for 
Reporting  Back -up 
Method 
of 
Reporting  
PC (if 
investigator 
becomes 
aware)  Participation in 
study has ended  N/A Promptly  PC form  N/A 
Abbreviations: AE = adverse event; CRF  = case report  form ; ICF = informed consent form; N/A = not applicabl e; 
SAE  = serious adverse event ; PC = product complaint; TZP = tirzepatide . 
a Serious adverse events  should not be reported unless the investigator deems them to be possibly related to study 
treatment  or study participation . 
8.3.2.  Pregnancy   
Because of the pediatric population  (Tanner Stage 1) in the rare event of pregnancy , pregnancy 
information will be collected as follows:  
Collection of pregnancy information  
Female participants who become pregnant  
● The investigator will collect pregnancy information on any female participant 
who becomes pregnant while p articipating in this study. The initial information 
will be recorded on the appropriate form and submitted to the sponsor within 24 
hours of learning of a participant’s pregnancy.  
● The participant will be followed to determine the outcome of the pregnanc y. The 
investigator will collect follow -up information on the participant and the neonate 
and the information will be forwarded to the sponsor. Generally, follow -up will 
not be required for longer than 6 to 8 weeks beyond the estimated delivery date. 
Any t ermination of pregnancy will be reported, regardless of gestational age,  fetal 
status (presence or absence of anomalies) , or indication for the procedure.  
● While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective  termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
● A spontaneous abortion (occurring at <20 weeks gestational age) or still birth 
(occurring at ≥20 weeks gestational age) is always considered to be an SAE and 
will be repor ted as such.  
● Any post -study pregnancy -related SAE considered reasonably related to the study 
intervention by [CONTACT_170272] 8.3.1 . While the investigator is not obligated to actively seek this 
information in former study participants, he or she may learn of an SAE through 
spontaneous reporting.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
47 ● Any female participant who becomes pregnant while participating in the study . If 
the participant is discontinued from the study, follow the standard discontinuation 
process and continue directly to the follow -up phase. The follow -up on the 
pregnancy outcome should continue independent of in tervention or study 
discontinuation .  
Prior to the continuation of study intervention following pregnancy, the following must occur:  
● The sponsor and the relevant IRB/IEC give written approval.  
● The participant gives signed informed consent.  
● The investigator agrees to monitor the outcome of the pregnancy and the status of the 
participant and the participant’s offspring.  
8.3.3.  Adverse Events of Special Interest   
[IP_ADDRESS].  Hypersensitivity  Reactions   
Many drugs, but particularly biologic agents, carry the risk of systemic hypersensitivity 
reactions. If such a reaction occurs, additional data describing each symptom must be provided to 
the sponsor in the eCRF.  
Sites should  have appropriately trained medical staff and appropriate medical equipment 
available when study participants are receiving study intervention . It is recommended that 
participants who experience a sys temic hypersensitivity reaction be treated per national and 
international guidelines.  
In the case of generalized urticaria or anaphylaxis, additional blood samples should  be collected 
as described in Appendix 8 (Section  10.8). Laboratory results are provided to the sponsor via the 
central laboratory.  
[IP_ADDRESS].  Injection -Site Reactions   
Symptoms and signs of a local injection site reaction ( ISR) may include erythema, induration, 
pain, pruritus, and edema.  
If an ISR is reported by a participant or parent or guardian or site staff, the ISR CRF will be used  
to capture additional information about this reaction, for example, injection -site pain, degree and 
area of erythema, induration, pruritis , and edema.  
At the time of AE occurrence in the tirzepatide group, samples will be collected for the 
measurement of tirzepatide antidrug antibodies  and tirzepatide concentration . 
[IP_ADDRESS].  Hypoglycemia Reporting   
Participants will be trained by [CONTACT_543085].  
Investigators should use the following classification of hypoglycemia:  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
48 Level 1 hypoglycemia :  
Glucose <70 mg/dL (3.9 mmol/L) and ≥ 54 mg/dL (3.0 mmol/L): Level [ADDRESS_708768] -acting carbohydrates. Providers should 
continue to counsel participants to treat hypoglycemia at this glucose alert value.  
Level 2 hypoglycemia:  
Glucose <54 mg/dL (3.0 mmol/L): Level 2 hypoglycemia is also referred to as documented or 
blood glucose confirmed hypoglycemia with glucose <54 mg/dL (3.0 mmol/L). This glucose 
threshold is clinically relevant regardless of the presence or absence of symptoms of 
hypoglycemia.  
Level 3 hypoglycemia : 
Severe hypoglycemia (in adults): A severe event  characterized by [CONTACT_226405]/or physical 
status requiring assistance for treatment of hypoglycemia. For example,  
participants had altered mental status, and could not assist in their own care, or were 
semiconscious or unconscious, or experienced co ma with or without seizures, and the assistance 
of another person was needed to actively administer carbohydrate, glucagon, or other 
resuscitative actions. Glucose measurements may not be available during such an event, but 
neurological recovery attributab le to the restoration of glucose concentration to normal is 
considered sufficient evidence that the event was induced by a low glucose concentration.  
The determination of a hypoglycemic event as an epi[INVESTIGATOR_66677], as defined 
above, is made by [CONTACT_543086] a participant simply having received assistance.  
If a hypoglycemic event meets the criteria of severe hypoglycemia, the inve stigator must record 
the event as serious on the AE CRF and report it to Lilly as an SAE.  
Nocturnal hypoglycemia:   
Nocturnal hypoglycemia is a hypoglycemia event (including severe hypoglycemia) that occurs at 
night and presumably during sleep.  
[IP_ADDRESS].  Nausea and V omiting   
Nausea and vomiting events are considered AEs of interest and will be recorded as AEs in the 
CRF. For each event assessment of severity, duration and investigator’s opi[INVESTIGATOR_543046].  
[IP_ADDRESS].  Elevated Lipase or Amylase   
Serum amylase and lipase measurements will be collected as a part of the clinical laboratory 
testing at time points specified in the SoA (Section  1.3). Additional measurements may be 
performed at the investiga tor’s discretion. Further diagnostic assessments will be recommended 
whenever lipase or amylase is confirmed to be ≥3X ULN at any visit post  randomization, even if 
the participant is asymptomatic  (as per the algorithm refer for the monitoring of pancreatic  
events  in Appendix 6, Section  10.6). 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
49 8.4. Pharmacokinetics   
The c haracterization of the PK properties of tirzepatide in pediatric participants will be supported 
by [CONTACT_543087] (Section 1.3).  
At Visit 2  (Day s 1 to 3), the sample is collected at  [ADDRESS_708769] dose 
during inpatient visit.  At Visit  6 (Day s 23 to 25), each participant will have PK sample  collect ed 
at window of [ADDRESS_708770]  Day 22  dose. At Visit 9 (Day s 41 and 42), each participant will 
have PK sample collected at window of [ADDRESS_708771]  Day 36  dose.  For Visit s 4, 8, and 
11 (Day s 15, 36, and 50), PK samples are collected prior to the intervention administration.  
Participants may be required to come to the site for PK -specific visits depending on sample 
window.  
The actual  date and time of the most recent SC injection administered prior to collecting the 
sample m ust be recorded. The actual date and time at which each sample was drawn must be 
recorded on the laboratory  requisition form. Instructions for the collection and handling of blood 
samples will be provided by [CONTACT_456].   
The number and timing of PK sample s are expected to be adequate in enabling comprehensive 
population PK  and exposure -response modeling analyses within this special population.  
8.4.1.  Bioanalysis   
Samples will be analyzed  at a laboratory approved by [CONTACT_17077] a facility 
designated by [CONTACT_456] . 
Concentrations of tirzepatide will be assayed using a validated liquid chromatography mass 
spectrometry method. The analyses of samples collected from placebo -treated participants  are 
not planned . 
Bioanalytical samples collected to measure study intervention  concentrations will be retained for 
a maximum of [ADDRESS_708772] participant  visit for the study. During thi s time, samples 
remaining after the bioanalyses may be used for exploratory analyses such as metabolism, 
protein binding, or bioanalytical method cross -validation.  
8.5. Pharmacodynamics   
The PD exploratory  analys es include  treatment comparison based on  the following variables:  
 body weight  
 BMI , and  
 waist circumference . 
8.5.1.  Body Weight  and Waist Circumference   
Weight and wai st circumference  will be measured as indicated in the SoA (Section 1.3). 
Wherever possible, the same scale will be used for all weight  measurements throughout the study 
and the scale will not be moved or recalibrated.  
Refer to Section 10.[ADDRESS_708773] 
circumference measurements.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
50 8.6. Genetics   
Genetics are not evaluated in this study.  
8.7. Biomarkers   
Biomarkers are not evaluated in this study.  
8.8. Immunogenicity Assessments   
At the visits and times spec ified in the SoA (Section 1.3), venous blood samples will be collected 
to determine antibody production against tirzepatide . Samples with detected tirzepatide ADA  
will be titered and evaluated for their ability to neutralize tirzepatide activity on the GIP and 
GLP -[ADDRESS_708774] 
native GIP and GLP -1. To interpret the results of immunogenicity, a venous blood sample will 
be collected at the same time points after predose visit (Day 1)  to determine t he serum 
concentrations of tirzepatide . Detailed instructions for the sample collections and handling will 
be provided by [CONTACT_456]. Immunogenicity will be assessed by a validated assay designed to 
detect ADAs in the presence of tirzepatide at a laborato ry approved by [CONTACT_456].  
Treatment -emergent ADAs (TE ADA ) are defined in Section  9.3.[ADDRESS_708775] for additional samples to be taken until the signal returns to  
baseline ( that is,  no longer indicates TE  ADA) or for up to [ADDRESS_708776] be included in the ICF. 
Refer to Appendix 1 (Section 10.1.9 ) for details on sample retention .  
8.9. Health Economic s  
Health econo mics or medical resource utilization and health economics parameters are not 
evaluated in this study . 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708777] important endpoints , including 
primary and key secondary endpoints.  
9.1. Statistical Hypotheses   
Not applicable.  
9.1.1.  Multiplicity Adjustment   
Not applicable. No formal statistical analysis will be performed.   
9.2. Analyses  Sets  
For the purposes of analysis, the following analysis sets are defined:  
Participant Analysis Set  Description  
Full analysis set  All enrolled participants. Participants will be included in the 
analyses according to the planned intervention.  
Safety analysis set  All participants who are exposed to study intervention. Participants will be 
analyzed according to the intervention they actually received.  
The full analysis set will be used to summarize disposition  and demographic  characteristics.  
The safety analysis se t will be used for  safety  evaluation . 
9.3. Statistical Analyses   
9.3.1.  General Considerations   
Statistical analysis of this study will be the responsibility o f the sponsor or its designee.  
PK analyses will be conducted on data from all participants who receive at least [ADDRESS_708778] evaluable PK.  
Safety analyses will be conducted fo r all enrolled participants who were administered study 
intervention, whether or not they completed all protocol requirements.  
A detailed description of participant disposition will be provided at the end of the study. 
All participants  who discontinue from  the study will be identified, and the extent of their 
participation in the study will be reported. If known, a reason for their discontinuation will be 
given.  
The demographic characteristics of enrolled participan ts (including but not limited to  age, sex,  
and race) will be summarized . Additional exploratory analyses of the data will be conducted as 
deemed appropriate.  
 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
52 9.3.2.  Pharmacokinetic s  
[IP_ADDRESS].  Pharmacokinetic Analyses   
All tirzepatide concentration data will be listed and summa rized using descriptive analysis. 
Tirzepatide concentration may also be analyzed using a population PK approach via nonlinear 
mixed -effects modeling with the NONMEM ® software  to determine the  Cmax and AUC 0-tau of 
tirzepatide  by [CONTACT_543088] .  
[IP_ADDRESS].  Pharmacokinetic Statistical Inference   
No formal statistical analysis will be performed . 
9.3.3.  Safety Analyse s  
[IP_ADDRESS].  Clinical Evaluation of Safety   
All study  intervention  and protocol procedure AEs will be listed, and if the frequency of events 
allows, safety data will be summarized using descriptive methodology.  
The incidence of AEs will be presented by [CONTACT_543089]. AEs reported to occur prior to enrollment will be distinguished 
from those reported as new or increased in severity during the study. Each AE will be classified 
by [CONTACT_154711].  
The number of study intervent ion-related SAEs will be reported.  
[IP_ADDRESS].  Statistical Evaluation of Safety   
Safety parameters that will be assessed include safety laboratory parameters, vital signs  
(including blood pressure and pulse rate ), body weight and BMI, and ECG parameters. 
Continuous safety variables will be summarized using descriptive statistics. Categorical safety 
variables will be summarized using count and percentage.  
Additi onal analysis will be performed if warranted upon review of the data.  
9.3.4.  Evaluation of Immunogen icity  
The frequency and percentage of participants  with preexisting ADA s, ADAs at any  time 
postbaseline,  and TE ADA+  to tirzepatide may be tabulated. TE ADAs  are defined as those with 
a titer 2 -fold (1 dilution) greater than the minimum required dilution (1:10) of the ADA assay if 
no ADAs were detected at baseline (treatment -induced ADA) o r those with a 4 -fold (2 dilutions) 
increase in titer compared to baseline if ADAs were detected at baseline (treatment -boosted 
ADA). For the TE ADA+ participants, the distribution of maximum titers may be described. The 
frequency of neutralizing antibodie s, if assessed, and cross -reactivity to native GIP and GLP -1 
may also be tabulated in TE ADA+ participants . 
The relationship between the presence of antibodies and the PK parameters and PD response, 
including safety and efficacy to tirzepatide,  may be asse ssed.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708779]  
participants each, exposed to tirzepatide , for the weight categor ies <50 kg and ≥[ADDRESS_708780] 1 evaluable PK sa mple. The sample size is customary for Phase 1 
studies evaluating safety, tolerability, and PK, and is not powered on the basis of any a priori 
statistical hypothesis testing for efficacy.  
Participants who do not complete all the study procedures may be re placed to achie ve the 
planned number of completers . 
Note:  Enrolled means a participant’s  parent  or their legally acceptable representative’s, 
agreement to participate in a clinical study following the completion of the informed consent 
process and assent where applicable  and screening. Potential participants who are screened for 
the purpose of determining eligibility for the study, but do not participate in the study, are not 
considered enrolle d. A participant will be considered as enrolled if the informed  consent is not 
withdrawn prior to participating in any study activity after the screening  visit. 
Approved on 16 Nov 2023 GMT
CCI
C
C
I
CONFIDENTIAL  I8F-MC-GPHV (e) 
54 10. Supporting Documentation and Operational Considerations   
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations   
10.1.1.  Regulatory and Ethical Considerations   
This study will be  conducted in accordance with the protocol and with the following:  
 consensus  ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS ) Internationa l Ethical 
Guidelines  
 applicable International Council for Harmoni zation of Technical 
Requirements for Pharmaceuticals for Human Use  (ICH) GCP  Guidelines , 
and 
 applicable  laws and regulations . 
The protocol, protocol amendments, ICF,  applicable assent forms , Investigator Brochure, and 
other relevant documents ( for example , advertisements) must be submitted to an IRB/IEC by [CONTACT_52009]/IEC  before the study is initiated.  
Any amendments to the protocol will require IRB/IE C approval before implementation  of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
Protocols and any substantial amendments to the protocol will require health authority approval 
prior  to initiation except for changes necessary to eliminate an immediate hazard to study 
participants . 
The investigator will be responsible for the following:  
 providing  written summaries of the status of the study to the IRB/IEC 
annually or more frequently in  accordance with the requirements, policies, 
and procedures established by [CONTACT_1201]/IEC  
 notifying  the IRB/IEC of SAEs  or other significant safety findings as 
required by [CONTACT_1744]/IEC procedures , and  
 providing  oversight of study conduct for participants under the ir 
responsibility and adherence to requirements of 21 C ode of Federal 
Regulations (C FR), ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations . 
Investigator sites are comp ensated for participation in the study  as detailed in the clinical trial 
agreement . 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
55 10.1.2.  Informed Consent Process   
The investigator or the investigator’s  representative will explain the nature of the study , 
including the risks and benefits,  to the participant or the participant’s  legally authorized 
representative , defined as either a parent or a legal  guardian  and answer all  questions regarding 
the study.  
Participants must be informed that their participation is voluntary. Participants or their legally 
authorized representative s will be required to sign a statement of informed consent that meets the 
requirements of 21 CFR 50, local regulations, ICH guidelin es, privacy and data protection 
requirements, where applicable, and the I RB/IEC or study center.  
The medical record must include a statement that written informed consent was obtained before 
the participant was enter ed in the study and the date the written  consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
Participants must be reconsented to the most current version of the ICF(s) during th eir 
participation in the study.  
A copy of the ICF(s) must be provided to  the participant or the participant’s legally authorized 
representati ve and is kept on file . 
10.1.3.  Data Protection   
Participants will be assigned a unique identifier by [CONTACT_456]. Any  participant , parent  or legal 
guardian  records , datasets  or tissue samples  that are transferred to the sponsor will contain the 
identifier only; participant names or any information which would make the participant , parent or 
legal guardian  identi fiable , will not be transferred.  
The paren t or legal guardian  must be informed that the participant’s  personal study -related data 
will be used by [CONTACT_10999]. The level of disclosure 
must also b e explained to the partici pant who will be required to give consent for their data to be 
used as described in the informed consent .  
The participant must be informed that their medical records may be examined by [CONTACT_11000], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].  
The sponsor has processes in place to ensure data  protection, information security and data 
integrity. These processes include appropriate contingency plan(s) for appropriate and timely 
response in the event of a data security breach.  
Rationale for collection of full date of birth  
This study includes chi ldren. Within this age range, participants’ expected height and weight, as 
well as normal ranges for laboratory tests, vary by [CONTACT_543090]. Therefore, it is necessary to 
collect the full date of birth (day, month, and year) for all participants to app ropriately analyze 
and interpret changes in growth and laboratory parameters.  
In countries where local regulations do not permit collection of the full date of birth, if the 
supporting regulatory/ethics documentation is available, at a minimum, the month a nd year of 
birth must be collected on the eCRF.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
56 10.1.4.  Dissemination of Clinical Study Data   
Communication of Suspended or Terminated Dosing  
If a decision is taken to suspend or terminat e dosing in the trial due to safety findings, this 
decision will be communicated by [CONTACT_543091] (for example, by [CONTACT_16476]) as soon as possible. It will be a requirement that investigators respond upon receipt to 
confirm that they  understand the communication and have taken the appropriate action prior to 
further dosing any participants with study intervention. Any investigator not responding will be 
followed up by [CONTACT_543092]. If a dos e is planned 
imminently, The sponsor  personnel will immediately, and continually, use all efforts to reach 
investigators until contact [CONTACT_17086].  
Reports  
The sponsor will disclose a summary of study information, including tabular st udy results, on 
publicly available websites where required by [CONTACT_51967].  
Data  
The sponsor does not proactively share data from Phase 1 clinical trials. Requests for access to 
Phase 1 clinical trial data are evaluated on a case by [CONTACT_543093].  
10.1.5.  Data Quality Assurance   
All participant data relating to the study will be recorded on printed or electronic CRF s unless 
transmitted to the sponsor or designee electronically ( for example , laboratory data). The 
investigator is responsible for verifying that data entries are accurate and correct by [CONTACT_543094].  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in  the CRF.  
Source data may include laboratory tests, medical records, and clinical notes.  
The investigator must permit study -related mo nitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct a ccess to source data documents.  
Quality tolerance limits will be predefined to identify systematic issues that can impact 
participant safety or reliability of study res ults. These predefined parameters will be monitored 
during the study and important excursions  from the quality tolerance limits ( QTLs ) and remedial 
actions taken will be summarized in the clinical study report . 
Monitoring details describing strategy ( for example , risk -based initiatives in operations and 
quality such as risk management and mitigation strategies and analytical risk -based monitori ng), 
methods, responsibilities and requirements, including the handling  of noncompliance issues and 
monitoring tec hniques , are provided in the Trial Monitoring Plan.  
The sponsor or designee is responsible for the data management of this study includin g quality 
checking of the data.  
The sponsor assumes accountability for actions delegated to other individuals ( for exam ple, 
contract research organizations ). 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
57 Study monitors will perform ongoing source data verification to confirm that data transcribed 
into the CRF by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and  rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regu latory requirements.  
Records and documents, including sign ed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_543095] a longer retention period. No records may be 
destr oyed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party without written notification to the sponsor . 
In addition, sponsor  or its representatives will periodically check a samp le of the participant data 
recorded against source documents at the study site. The study may be audited by [CONTACT_517513], and/or regulatory agencies at any time. Investigators will be given notice before 
an audit occurs.  
Data Capture Syst em 
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.   
An electronic data capture  system  will be used in this study for the collection of CRF data. The 
investigator maint ains a separate source for the data entered by [CONTACT_52012] -provided electronic data capture  system. The investigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by [CONTACT_11003] . 
Data collected via the sponsor -provided data capture system will be  stored at third  parties . The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data capture system (s). Prior to decommissioning, the investigator will receive or access 
an archival copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central ven dor’s database system and reports  will be provided to the investigator for review 
and retention. Data will subsequently be transferred from the central vendor to the sponsor  data 
warehouse.  
Data from complaint forms submitted to the sponsor  will be encoded  and stored in the global PC 
management system.  
10.1.6.  Source Documents   
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data  collected. Source documents are filed at the investigator’s site.  
Data reported  on or entered in the CRF and are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator 
may need to request previous medical records or transfer records, depending on the study. Also, 
current medical records must be available.  
Definition of what constitutes source data can be found in  Section 10.1.5 . 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708781] of Rec ruitment  
The study start date is the date on which the clinical stud y will be open for the recruitment of 
participants.  
Study or Site Termination  
The sponsor or sponsor’s designee reserves the right to close the study site or terminate the study 
at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon 
study completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, prov ided that there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]:  
for study termination : 
 discontinuati on of further study intervention development  
for site termination : 
 failure  of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
 inadequate  recruitment (evaluated after a reasonable amount of time) of 
participants by [CONTACT_093] , and  
 total number of participants included earlier than expected . 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The investigator shall promptly inform  the participant  and should assure 
appropriate participant  therapy (if applicable) and follow -up. 
10.1.8.  Publication Policy   
In accordance with the sponsor’s publication policy, the resu lts of this study will be submitted 
for publication by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.  
10.1.9.  Sample Retention   
Sample retentio n enables the use of new technologies, response to regulatory questions, and 
investigation of variable response that may not be observed until later in the development 
of tirzepatide  or after  tirzepatide  become(s) commercially available for the studied ind ication.  
  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708782] 
Patient Visit a 
Pharmacokinetics  Sponsor or designee  1 year 
Immunogenicity  Sponsor or designee  15 years  
a Retention periods may differ locally.  
 
10.2. Appendix 2: Clinical Laboratory Tests   
The tests detailed in the table below will be performed by [CONTACT_2237] . 
Local laboratory results are only required in the event that the central laboratory results are not 
available in time for either study intervention administration or response evaluation. If a local 
sample is required, it is important that the sample for central analysis is obtained at the same 
time.  Additionally, if the local laboratory results a re used to make either a study intervention 
decision or response evaluation, the results must be recorded . 
In circumstances where the sponsor approves local laboratory testing in lieu of central laboratory 
testing (in the table below), the local laboratory  must be qualified in accordance with applicable 
local regulations.  
Protocol -specific requirements for inclusion or exclusion of participants are detailed in Section  [ADDRESS_708783] document their review of the laboratory safety results .  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
60 Safety Laboratory Tests  
Hematology a Clinical chemistry (fasting) a 
Hematocrit  Sodium  
Hemoglobin  Potassium  
Erythrocyte count (RBC)  Bicarbonate  
Mean cell volume  Chloride  
Mean cell hemoglobin  Calcium  
Mean cell hemoglobin concentration  Glucose  
Leukocytes (WBC)  Blood urea nitrogen  
 Total protein  
Absolute counts of a: Albumin  
Neutrophils  Total bilirubin  
Lymphocytes  Alkaline phosphatase  
Monocytes  Aspartate aminotransferase  
Eosinophils  Alanine aminotransferase  
Basophils  Creatinine  
Platelets  Amylase  
 Lipase  
Pubertal hormone a: 
Testosterone (male participants only)  
Estradiol (female participant only)  Uric acid  
Phosphorous  
Calcitonin c 
Insulin  
Urinalysis a 
Specific gravity  Lipid panel ( fasting) a,b 
pH Triglycerides  
Protein  Total cholesterol  
Glucose  LDL  
Ketones  HDL  
Bilirubin   
Hepatitis C antibody, hepatitis C RNA c,d 
Urobilinogen  HIV c,d 
Blood  Hepatitis B surface antigen c,d 
Nitrite  Urine pregnancy test e 
Microscopic examination of sediment f  
Abbreviations: LDL = low -density lipoprotein; HIV = human immunodeficiency virus; HDL = high -density 
lipoprotein; RBC = red blood cells; RNA = ribonucleic acid; WBC = white blood cells.  
a Performed by [CONTACT_543096] , which will be by [CONTACT_12117] . Results will be validated 
by [CONTACT_105429].  
b Performed at screening  (by [CONTACT_12117]) , Visit 2 (central laboratory) , and Visit 12  or at early discontinuation visit 
(central laboratory) . 
c Performed by [CONTACT_543097].  
d Tests may be waived if they have been performed within [ADDRESS_708784] only if dipstick result is abnormal ( that is , positive for blood, protein, or nitrites).  
  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
61 10.2.1.  Blood Samp ling Summary   
The table below summarizes the approximate number of venipunctures and blood volumes for  all 
blood sampling (screening, safety laboratories, and bioanalytical assays) during the  study. The 
number of samples in parenthesis assumes 3 additional unscheduled samples , which may be 
taken for safety purpose s. 
To ease discomfort associated with venipunctures, the  follow ing options are allowed in the study 
per local practice and prescribing information:  
 local anesthetic creams, for example, EMLA® or ELA -max®  
 needleless devices for injecting local anesthetics, for example, a J -tip, and  
 local vibration devices, for example , a buzzy.  
 
Protocol I8F -MC-GPHV Overall Sampling Summary  
Purpose  Blood Volume per Sample 
(mL) Number of Blood 
Samples  Total Volume 
(mL) 
Screening tests a,b 20 1 20 
Safety laboratory tests a,c 12 3 36 
Tirzepatide pharmacokinetics c 2 9 18 
Immunogenicity c 10 4 40 
Blood glucose a,b 2 2 4 
Total   118 
Total for clinical purposes    120 
a Additional samples may be drawn if needed for safety purposes. Safety laboratory tests will be inclusive of lipid 
panels on days when they are performed .  
b Performed on site or in a local laboratory.  
c Performed at a central or referral laboratory approved by [CONTACT_456] . 
 
[IP_ADDRESS].  Rationale for Blood Draws and Required Blood Volume   
Careful consideration was given to collect the necessary information to address the key scientific 
objectives of this pediatric study while also minimizing invasive procedures and overall patient 
burden . 
As PK profiling is a secondary objective of this study, the number of bioanalytical samples 
proposed is the minimum required to be able to derive a concentration -time profile for tirzepatide 
in children, based on an anticipated half -life of about [ADDRESS_708785] for ADA  and neutralizing antibodies using 4 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
62 aliquots ( approximately 1 mL serum per aliquot) of serum in the event that the ADA sample is 
positive.  A sample is required every 4 to 5 weeks , and another sample will als o be drawn 2 
weeks after initial treatment commencement to monitor IgM ADA  as is often explicitly  
requested  by [CONTACT_543098] .   
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
63 10.3. Appendix 3: Adverse Events  and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting   
The definitions and procedures detailed in this appendix are in accordance with ISO [ZIP_CODE].  
Both the investigator and the sponsor will comply with all local medical device reporting 
requirements.  
The detection and documentation procedures described in this protocol apply to all sponsor 
medical devices provided for use in the study. See Section 6.1.[ADDRESS_708786] a causal relationship with the study intervention. 
An AE can , therefore , be any unfavorable and unintended sign (including a n abnormal 
laboratory finding), symptom, or disease  (new or exacerbated)  temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product . 
An AE is any untoward medical occurrenc e, unintended disease or injury, or untoward clinical 
signs (including abnormal laboratory finding) in study participants, users, or other persons, 
whether or not related to the investigational medical device. This definition includes events 
related to the  investigational medical device or comparator and events related to the 
procedures involved except for events in users or other persons, which only include events 
related to investigational devices.  
 
Events meeting  the AE definition  
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments ( for ex ample , ECG, radiological scans, and vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the me dical and 
scientific judgment of the investigator ( that is , not related to progression of underlying 
disease).  
Exacerbation of a chronic or intermittent preexisting condition including either an increase in 
frequency or intensity of the condition.  
New cond ition detected or diagnosed after study intervention administration even though it 
may have been present before the start of the study.  
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
Signs, symptoms, or the clinical sequela e of a suspected overdose of either study intervention 
or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
64 an intentional overdose taken with possible suicidal/self -harming intent. Such overdose s 
should be reported r egardless of sequelae.  
 
Events not m eeting the AE definition  
Any clinically significant abnormal laboratory findings or other abnormal safety assessments 
that are associated with the underlying disease, unless judged by [CONTACT_543099]’s condition.  
The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
Medical or surgical proc edure ( for example , endoscopy and appendectomy): the condition that 
leads to the procedure is the AE.  
Situations in which an untoward medical occurrence did not occur (social or convenience 
admission to a hospi[INVESTIGATOR_307]).  
Anticipated day -to-day fluctuations of p reexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
10.3.2.  Definition of S erious Adverse Event  
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed : 
a. Results in death  
b. Is life -threatening  
The term life-threatening  in the definition of serious  refers to an event in which the participant 
was at risk of death at the time of th e event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_1081]  
 In general, hospi[INVESTIGATOR_51955] (usually involving at least an overnight stay) for observation or 
treatment that would not have been appropriate in the physician’s office or outpatient 
setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication 
prolongs hospi[INVESTIGATOR_9236], the event is serious. When 
in doubt as to whether hospi[INVESTIGATOR_51956], the  AE should be 
considered serious.  
 Hospi[INVESTIGATOR_543047] a preexisting condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent disability  or incapacity  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
65  The term disability means a substantial disru ption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma ( for example , sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly  or birth defect  
 Abnormal pregnancy outcomes ( for example , spontaneous abortion, fetal death, 
stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.  
f. Other situations  
 Medical or scientific judgment should be exercised by [CONTACT_170280] -threatening or result in death or hospi[INVESTIGATOR_51957]. These events s hould 
usually be considered serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or 
drug abuse.   
g. Resulted in medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body structure or a body function.   
10.3.3.  Definition of Product Complaints   
Product complaint  
A PC is any written, electronic, or oral communication that alleges deficiencies related to the 
identity, quality, durability, reliability, safety, effectiveness , or performance of a study 
intervention . When the ability to use the study intervention safely is impacted, the following 
are also PCs: 
 deficiencies in labeling information, and  
 use errors for device or drug-device combination products due to ergonomic design 
elements of the product.  
PCs related to study inte rventions used in clinical trials are collected in order to ensure the 
safety of participants, monitor quality, and facilitate process and product improvements.  
Investigators will instruct participan ts to contact [CONTACT_543100] a 
PC or problem with the study inte rvention so that the situation can be assessed.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708787] complaint  recording  
When an AE/SAE /PC occurs, it is the responsibility of the investigator to review all 
documentation ( for example , hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics 
reports) related to the event.  
The investigator will then record all relevant AE/ SAE /PC information in the participant’s 
medical records, in accordance with the investigator’s normal clinical practice. AE/SAE 
information is reported on the appropriate CRF page , and PC information is reported on the 
PC form. 
Note:  An event may meet the definition of both a PC and an AE/SAE. In such cases, it 
should be reported as both a PC and as an AE/SAE.  
It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to sponsor  or designee  in lieu of completion of the CRF page  for AE/SAE and the PC 
form for PCs. 
There may be instances when copi[INVESTIGATOR_10915] . In this case, all participant identifiers, with the exception of the 
partici pant number, will be redacted on the copi[INVESTIGATOR_10916] . 
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
or other clinical information. Whenever possible, the  diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
Assessment of intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to one of the following categories:   
 Mild:  A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of 
daily living.  
 Moderate:  A type of AE that is usually alleviated with addition al specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.  
 Severe: A type of AE that interrupts usual activities of da ily living, or significantly 
affects clinical status, or may require intensive therapeutic intervention . An AE that is 
assessed as severe should not be confused with a SAE. Severe is a category utilized for 
rating the intensity of an event , and both AEs an d SAEs can be assessed as severe.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
67 An event is defined as “serious ” when it meets at least one of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of causality  
The investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE.  The investigator will use clinical judgment to determine the 
relationship . 
A “reasonable possibility ” of a relationship conveys that there are facts, evidence, and 
argum ents to suggest a causal relationship, rather than a relationship cannot be ruled out.  
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, 
as well as the temporal relationship of the event to study intervention a dministration will be 
considered and investigated.  
The investigator will also consult the IB in their assessment.  
For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of cau sality.  
There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to sponsor or designee . However, it is very 
important that the investigator always make an assessment of causality for every event before 
the initial transmission of the SAE data to sponsor or designee . 
The investigator may change their opi[INVESTIGATOR_9242] -up information and 
send a SAE follow -up report with the updated causality assessment.  
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
 
Follow -up of AEs and SAEs  
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements or evaluations as medically indicated or as requested by [CONTACT_543101]. This m ay include 
additional laboratory tests or investigations, histopathological examinations, or consultation 
with other healthcare professionals.  
If a participant dies during participation in the study or during a recognized follow -up period,  
the investigator  will provide sponsor or designee  with a copy of any postmortem findi ngs 
including histopathology . 
 
 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708788] the safety of participants and the safety of a 
study intervention under clinical investigation are met.  
The sponsor has a le gal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country -specific regulatory requirements relating to safety r eporting 
to the regulatory authority, IRB/IEC, and investigators.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information ( for example , summary or listing of SAEs) from the sponsor will review 
and th en file it along with the IB and will notify the IRB/IEC, if appropriate according to local 
requirements.   
  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
69 10.4. Appendix 4: Contraceptive and Barrier Guidance   
10.4.1.  Definitions   
Women of Childbearing Potential  
Females less than [ADDRESS_708789]  
 had at least 1 cycle of menses, or  
 Tanner Stage [ADDRESS_708790] development  (see Tanner Staging,  Section 10.7 [Appendix 7]). 
Any amount of spotting should be considered menarche.  
Women not of Childbearing Potential  
Females are considered women not of childbearing potential if  
 they have breast develop ment Tanner 1, or  
 they have a congenital anomaly such as Mullerian agenesis, or  
 they are infertile due to surgical sterilization.  
Examples of surgical sterilization include hysterectomy, bilateral oophorectomy, and tubal 
ligation.  
10.4.2.  Contraception Guidance   
Not applicable . 
10.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments   
Hepatic Evaluation Testing  
See protocol Section  8.2.[ADDRESS_708791] or calculation is available.   
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
70  
Tests assayed by [CONTACT_11007] -designated central laboratory  
Hepatic Hematology Panel  Hepatitis A virus (HAV) testing:  
   Hemoglobin      HAV total antibody  
   Hematocrit      HAV IgM antibody  
   Erythrocytes (RBCs - red blood cells)  Hepatis B virus  (HBV) testing:  
   Leukocytes (WBCs - white blood cells)      Hepatitis B surface antigen (HBsAg)  
   Differential:      Hepatitis B surface antibody (anti -HBs)  
       Neutrophils, segmented      Hepatitis B core total antibody (anti -HBc)  
       Lymphocyte s     Hepatitis B core IgM antibody  
       Monocytes      HBV DNA  b 
       Basophils  Hepatis C virus (HCV) testing:  
       Eosinophils      HCV antibody  
   Platelets      HCV RNA  b 
   Cell morphology (RBC and WBC)  Hepatitis D virus (HDV) testing:  
Hepatic Clinical Chemistry Panel      HDV antibody  
   Total bilirubin  Hepatitis E virus (HEV) testing:  
   Direct bilirubin      HEV IgG antibody  
   Alkaline phosphatase (ALP)      HEV IgM antibody  
   Alanine aminotransferase (ALT)      HEV RNA b 
   Aspartate aminotransferase (AST)  Anti -nuclear antibody (ANA)  
   Gamma -glutamyl transferase (GGT)  Anti -smooth muscle antibody (ASMA) a 
   Creatine kinase (CK)  Anti -actin antibody c 
Hepatic Coagulation Panel  Immunoglobulin IgA (quantitative)  
   Prothrombin time, INR (PT -INR)  Immunoglobulin IgG (quantitative) 
Urine Chemistry  Immunoglobulin IgM (quantitative)  
   Drug screen  Epstein -Barr virus (EBV) testing:  
Haptoglobin      EBV antibody  
Acetaminophen protein adducts   
 
Tests assayed ONLY by [CONTACT_1697] -designated local laboratory  
Acetaminophen  Cytomegalovirus (CMV) testing:  
     CMV antibody  
Alkaline phosphatase isoenzymes      CMV DNA  b 
Ceruloplasmin  Herpes simplex virus (HSV) testing:  
Copper      HSV (Type 1 and 2) antibody  
Ethyl alcohol (EtOH)      HSV (Type 1 and 2) DNA  b 
Phosphatidylethanol (PEth)  Liver kidney microsomal type 1 (LKM -1) antibody  
Urine Chemistry  Microbiology  
    Ethyl glucuronide (EtG)  Culture:  
Epstein -Barr virus (EBV) testing:      Blood  
    EBV DNA  b     Urine  
Abbreviations: CMV= c ytomegalovirus; EBV = Epstein -Barr virus; HAV = h epatitis A virus; HBV = h epatis B 
virus; HCV  = hepatis C virus; HDV = hepatitis D virus; HEV = hepatitis E virus; HSV = herpes simplex virus; 
IgA; IgG; IgM; INR; PT -INR; RBC =  red blood cells; WBC = white blood cells.  
a Not required if anti -actin antibody is tested.  
b Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
c Not required if anti-smooth  muscle antibody  is tested.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
71 10.6. Appendix 6: Pancreatic Monitoring   
 
Abbreviations: CT = computed tomography; MRI = magnetic resonance imaging; ULN = upper limit of normal.  
 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
72 Participants diagnosed with pancreatitis will be discontinued from the study. Investigators will 
be responsible for following, through an appropriate healthcare option, these pancreatitis AEs 
until the events resolve or are explained. AEs that meet the dia gnostic criteria of acute 
pancreatitis will be captured as SAEs. For all other pancreatic AEs (such as idiopathic or 
asymptomatic pancreatic enzyme abnormalities), the investigator will be responsible for 
determining the seriousness of the event (AE or SAE ) and the relatedness of the event to study 
drug.
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
73  
10.7. Appendix 7: Tanner Staging   
Tanner Stages guidelines for measurement of pubescence (Marshall and Tanner 1969, 
1970)  
Boys: Develo pment of external genitalia  
Stage 1 .  Prepubertal  
Stage 2 .  Enlargement of scrotum and testes; scrotum skin reddens and changes in 
texture  
Stage 3 .  Enlargement of penis; further growth of testes  
Stage 4 .  Increased size of penis; testes and scrotum larger, scrotum skin darker  
Stage 5 .  Adult genitalia  
Girls: Breast development  
Stage 1 .  Prepubertal ( no glandular tissue: areola follows the skin contours of the chest)  
Stage [ADDRESS_708792] bud stage with the enlargement of areola ( breast bud forms, with small 
area of surrounding glandular tissue; areola begins to widen)   
Stage [ADDRESS_708793] and areola ( breast begins to become more 
elevated, and extends beyond the borders of the areola, whi ch continues to 
widen but remains in contour with surrounding breast)  
Stage 4 .  Areola and papi[INVESTIGATOR_141878] a mound ( increased breast size and elevation; areola 
and papi[INVESTIGATOR_141878] a secondary mound projecting from the contour of the 
surrounding breast)  
Stage 5 .  Mature stage ( breast reaches final adult size; areola returns to contour of the 
surrounding breast, with a projecting central papi[INVESTIGATOR_9387])  
Boys and girls: Pubic hair  
Stage 1 .  Prepubertal (no pubic hair at all; can see vellus hair similar to abdominal wall )  
Stage 2 .  Sparse growth of long, slightly pi[INVESTIGATOR_21899], straight or curled ( small amount 
of long, downy hair with slight pi[INVESTIGATOR_543048] [males] or on the labia majora [females])  
Stage 3 .  Darker, coarser , and more curled hair, spreading sparsely over junction of pubes  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
74 Stage 4 .  Hair adult in type, but covering smaller area than in adult; no spread to medial 
surface of thighs  
Stage 5 .  Adult in type and quantity, with horizontal distribution ( “feminine ”) 
Note: The assessment of sexual maturity in children should include an assessment of age, 
growth , and menstrual history in addition to Tanner Staging. In case of discordance between 
breasts  or genitals vs pubic hair, the default should be breast  or genitals.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
75 10.8. Appendix 8: Laboratory Samples to be Obtained at the Time of a 
Systemic Hypersensitivity Event   
Purpose of collecting samples after a systemic hypersensitivity event  
The samples listed in this appendix are not collected for acute study participant management. 
The sponsor will use the laboratory tests results from these samples to characterize 
hypersensitivity events across the clinical development program.  
When to collect samples after a systemic hypersensitivity event occurs  
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the table, assuming the participant has been stabilized.  
Obtain follow -up pre -dose samples at the next regularly scheduled laboratory sample collection 
(ideally prior to the next dose after the event) to assess post -event return -to-baseline values.  
Timing  Preferred Sample 
Type a Laboratory Test b 
Collect from 30 minutes to 4 hours 
after the start of the event.  
 Note:  The optimal 
collection time is from 1 
to 2 hours after the start 
of event.  Serum  total tryptase  
Serum  complements ( C3, C3a, and C5a)  
Serum  cytokine panel ( IL-6, IL‐1β, IL‐10 or any 
cytokine panel that includes these 3 cytokines)   
Collect only if not already collected 
on the same day as the event.  
 Note:  If collecting, 
collect up to 12 hours 
after the start of the 
event.  Serum  Tirzepatide  anti-drug antibodies (ADA)  
Serum/plasma  Tirzepatide  concentration  
a Sample type may be different depending on local requirements.  
b All samples for hypersensitivity testing will be assayed by [CONTACT_11007] -designated laboratory. Results will not be 
provided to the study site. If samples are not collected or are collected outside the specified time period, this will 
not be considered a protocol deviation.  
Abbreviations: ADA = anti -drug antibodies; IL = interleukin.  
What information to record  
Record the date and time when the samples are collected.  
Allowed additional testing for participant management  
The investigator may perform additional tests  locally , if clinically indicated, for acute study 
participant management.  
10.9. Appendix 9: Standardized Protocols for the Measurement of Height, 
Weight, Waist C ircumference, and Vital Signs   
The following information has been adapted from standardized physical measurement protocols 
for the World Health Organization’s STEP wise approach t o Surveillance (STEPS) Manual 
(WHO  2017 ). 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
76 Measuring Height  
Step 1.   Ask the participant to remove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should  be worn by [CONTACT_291612]).  
Step 2.   Ask the participant to stand on the calibrated height measuring board (stadiometer) or 
against a wall with their feet together and their knees straight with their he els against the 
backboard,  the stadiometer , or the wall.  
Step 3.   Ask the participant to look straight ahead without tilting their head up.  
Step 4.   Ask the participant to breathe in and stand tall. If using a stadiometer or fixed measuring 
device, move th e device’s measurement arm gently down onto the top of the participant’s head. 
Record the participant’s height in centimeter  to [ADDRESS_708794].  
Measuring Weight  
 Body weight  measurements should be done in a consistent manner using a calibrated 
electronic s cale capable of measuring weight in kilogram  to [ADDRESS_708795] . 
 All weights for a given participant should be measured using the same scale, whenever 
possible, at approximately the same time in the morning after evacuation of bladder contents.  
 Participants should  be lightly clothed but not wearing shoes while their weight is measured.  
 Body weight must be measured in fasting state. If the participant is not fasting, the 
participant should be called in for a new visit within the visit window to ha ve the fasting 
body weight measured.  
Step 1 .  Ask the participant to remove their footwear, outerwear (coat, jacket, and so on ), and any 
headgear (light headgear worn for religious reasons can remain, but this should  be worn by [CONTACT_543102]).  
Step 2 .  Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a slopi[INVESTIGATOR_126154], or a rough, uneven surface).  
Step [ADDRESS_708796] one-tenth  kg. 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708797] Circumference  
Step 1.  Ask the participant to stand with their feet close together, and arms at their side with their 
body weight evenly distributed.  
Step 2.  Ask participant to relax.  
Step 3.  Measurements should  be recorded at the end of a normal expi[INVESTIGATOR_1516].  
 Waist circumference should be measured in the horizontal plane and at the midpoint 
between the lower mar gin of the last palpable rib and the top of the iliac crest . 
 Measurements should be taken at the end of a normal expi[INVESTIGATOR_157343] a nonstretchable 
measuring tape. The tape should lie flat against the skin without compressing the soft 
tissue.  
 The waist circumference should be measured twice, rounded to the nearest 0.5 cm. The 
measuring tape should be removed between the 2 measurements. Both measurements will 
be recorded in the eCRF. If the difference between the 2 measurements exceeds 1 cm, 
this set of m easurements should be discarded and the 2 measurements repeated.  
Vital Sign Measurements (blood pressure and heart rate)  
 Vital sign measurements should be taken before obtaining an ECG tracing and before 
collection of blood samples for laboratory testing.  
 An appropriately sized cuff (cuff bladder encircling at least 80% of the arm) should be 
used to ensure the accuracy of BP measurements.  
 Blood pressure should be taken with an automated blood pressure instrument.  
 If blood pressure and pulse measurements are  taken separately, pulse should be taken 
prior to blood pressure.   
 The participant should be supi[INVESTIGATOR_221865] 3  minutes before vital sign measurements are 
taken.  
Note:  In the event , pulse measurement cannot be taken via an automated blood pressure 
instrument, and the preferred location for measurement of pulse is the radial artery.   
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
78 10.10.  Appendix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances   
Implementation of this appendix  
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by [CONTACT_52019].  
Exceptional circumstances  
Exceptional circumstances are rare events that may cause disruptions to the conduct of the study. 
Examples include pandemics or natural disasters. These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement ch anges if permitted by [CONTACT_427].  
After approval by [CONTACT_31086], regulatory bodies and any other relevant local 
authorities, implementation of these exceptional circumstance changes will not typi[INVESTIGATOR_51960], unless they have specific requirements in which 
notification is required (for example, upon the implementation and suspension of changes). All 
approvals and notifications must be retained in the study records.  
If the sponsor grants written  approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if needed.  
Considerations for making a change  
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional impor tant considerations for making a change are compliance with GCP , enabling 
participants to continue safely in the study and maintaining the integrity of the study.  
Informed consent  
Additional consent and assent where applicable  from the participant will be obtained, if required, 
for 
 participation in remote visits, as defined in Section “Remote  Visits”  
 a change in the method of study intervention administration  
 dispensation of additional study intervention during an extended treatment 
period  
 alternate delivery of study intervention and ancillary supplies, and  
 provision of their personal or medical information required prior to 
implementation of these activities.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708798] will not be considered protocol deviations.  
Remote visits  
Types of remote visits  
Telemedicine : Telephone or technology -assisted virtual visits, or both, are acceptable to 
complete appropriate assessments. Assessments to be completed in this manner include, but are 
not limited to, concomitant medications , AE data capture , and self -performed body wei ght and 
height measures . 
Mobile healthcare : Healthcare visits may be performed by a mobile healthcare provider at 
locations other than the study site allowed per protocol (refer to the SoA in Section 1.3 for visits 
that are permitted to be conducted remotely) . Other than visits permitted per protoc ol, written 
approval must be  provided by [CONTACT_543103]. Procedures performed at such visits include, but are not 
limited to, AE documentation,  concomitant medications, collection of blood samples, collection 
of ECG and vital sign p arameters, physical assessments, administration of study intervention, 
and collection of health information.  
Data capture  
In source documents and the CRF, the study site should capture the visit method, with a specific 
explanation for any data missing bec ause of missed in -person site visits.  
Safety reporting  
Regardless of the type of remote visits implemented, the protocol requirements regarding the 
reporting of AEs, SAEs , and PCs remain unchanged.  
Return to on -site visits  
Every effort should be made to enable participants to return to on -site visits as soon as 
reasonably possible while ensuring the safety of both the participants and the site staff.  
Local laboratory testing option  
Local laboratory testing may be conducted in lieu of central laboratory te sting  for unscheduled  
events or as stipulated in Section 10.2. The local laboratory must be qualified in accordance with 
applicable local regulations.  
Study intervention and ancillary supplies (including participant diaries)  
When a  participant ’s parent or legal guardian  is unable to go to the site to receive study supplies 
during normal on -site visits, the site should work with the sponsor t o determine appropriate 
actions. These actions may include  
 asking the participant to go to the site and receive study supplies from site staff 
without the completion of a full study visit  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
80  asking the participant’s designee to go to the site and receive st udy supplies on a 
participant’s behalf, and 
 arranging the delivery of study supplies . 
The following requirements must be met before the action is taken:  
 Alternate delivery of study intervention should be performed in a manner that does 
not compromise treatment blinding and ensures product integrity. The existing 
protocol requirements for product accountability remain unchanged, including the 
verification o f participant’s receipt of study supplies.  
 When delivering supplies to a location other than the study site (for example, 
participant’s home), the investigator, sponsor, or both should ensure oversight of the 
shippi[INVESTIGATOR_543049] p roduct quality (that is, storage 
conditions maintained and intact packaging upon receipt).  
 Instructions may be provided to the participant or designee on the final disposition of 
any unused or completed study supplies . 
If study intervention will be administered to the participant during a mobile healthcare visit 
or at an alternate location, the following additional requirements must be met:  
 Only authorized study personnel may supply, prepare , or administer study 
interve ntion.  
 The mobile healthcare team must be able to handle and store study interventions in 
accordance to the requirements specified on the label.  
Screening period guidance   
To ensure the safety of study participants, laboratory values and other eligibility assessments 
taken at screening visit  are valid for a maximum of [ADDRESS_708799] be paused due to 
exceptional circumstances:  
 If screening is paused for  less than [ADDRESS_708800] the next visit if the participant’s eligibility criteria are 
confirmed, and the site should document the reason for delay.  
o Due to the pause in screening, sites should also reconfirm the impacted 
participant’s consent and  document this confirmation in the source 
documentation.  
 If screening is paused for more than [ADDRESS_708801] be 
discontinued because of screening interruption due to an exceptional circumstance.  
This is documented as a screen failure . 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708802] will be documented  
Sites will identify  and document the details of how participants, visits types, and conducted 
activities were affected by [CONTACT_52022]. Dispensing  or shipment records of study 
intervention and relevant communications, including delegation, should be filed with site study 
records.  
Source documents at alternate locations  
Source documents generated at a location other than the study site should be a part of the 
investigator’s  source documentation and should be transferred to the site in a secure and timely 
manner.   
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
82 10.11.  Appendix 11: Abbreviations  and Definitions   
Term  Definition  
ADA antidrug antibodies  
AE adverse event  
ALT alanine aminotransferase  
AST aspartate aminotransferase  
AUC 0-tau area under the concentration versus time curve from time 0 to the end of the dosing 
interval  
blinding  A double -blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the subjects 
are aware of the treatment received.  
BG blood glucose  
BMI body mass index  
Cmax maximum concentration  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, q uality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
CP clinical pharmacologis t 
CRF case report form; a printed, optical, or electronic document designed to record all of 
the protocol -required information to be reported to the sponsor for each trial 
participant.  
CRP  clinical research physician:  Individual responsible for the medical conduct of the 
study. Responsibilities of the CRP may be performed by a physician,  clinical research 
scientist, global safety physician or other medical officer.  
CRS  clinical research scientist  
CRU  clinical research  unit 
CV cardiovascular  
CVD  cardiovascular disease  
CT computed tomography  
ECG  electrocardiogram  
eCRF  electronic case report form  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
[ADDRESS_708803] been assigned to a treatment.  
enter  Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.  
GCP  good clinical practice  
GI gastrointestinal  
GIP glucose -dependent insulinotropic peptide  
GLP-1 glucagon -like peptide 1  
GLP-1R glucagon -like peptide 1 receptor  
HCV  hepatitis C virus  
IB Investigator’s Brochure  
IBT Intensive behavioral therapy  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committees  
IgM Immunoglobulin M  
informed consent  A process by [CONTACT_9444] a participant voluntarily confirms their willingness to participate 
in a particular study, after having been informed of a ll aspects of the study that are 
relevant to the participant’s decision to participate. Informed consent is documented by 
[CONTACT_3553] a written, signed and dated informed consent form . 
interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment 
groups, that is conducted before the final reporting database is created/locked.  
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, inclu ding products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the autho rized form.  
IRB Institutional Review Board  
ISR injection site reaction  
MRI magnetic resonance imaging  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
84 Term  Definition  
participant  equivalent to  CDISC term  “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control  
PC product complaint  
PK/PD  pharmacokinetics/pharmacodynamics  
RNA  ribonucleic acid  
SAE serious adverse event  
SC subcutaneous  
SoA schedule of activities  
screen  The act of determining if an individual meets minimum requirements to become part 
of a pool of potential candidates for participation in a clinical study.  
T2DM  type 2 diabetes mellitus  
TBL total bilirubin  
TE ADA  treatment -emergent ADA  
TE ADA+  treatment -emergent ADA positive  
ULN upper limit of normal  
  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
85 10.12.  Appendix 12: Protocol Amendment History   
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).  
Amendment [d]:  
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment:  
This protocol was amended to delete inconsistencies in protocol text regarding vital sign 
measurements and other minor changes for clarity .  
Section # and Name  [CONTACT_11029]  
10.9.  Appendix 9: Standardized 
Protocols for the Measurement of 
Height, Weight, Waist 
Circumference, and Vital Signs  Step [ADDRESS_708804] been removed.  
Amendment [c]: 05 June 2023  
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment:  
This protocol was amended to update the equation used for the exclusion criterion on renal 
impairment and other minor changes for clarity.   
Section # and Name  [CONTACT_9353] 1.3 Schedule of 
Activities  Clarified that the dose increase will occur at the 
fifth dose of TZP on Day 29 Week 5 and 
referenced Figure GPHV.1.1.  To provide information in the 
Schedule of Activities about 
when the TZP dose 
administered will increase to the 
next dose level.  
Section 2.3 Benefit/Risk 
Assessment  Clarified that female participants will be 
monitored for changes in Tanner stage.  To provide consistency 
throughout the protocol.  
Section 5.2 Exclusion 
Criteria  Updated the calculation used in Exclusion 
criterion #27 from Chronic Kidney Disease 
Epi[INVESTIGATOR_543050] 6.5 Dose 
Modification  Replaced stoppi[INVESTIGATOR_543051] a safety review and putting 
a pause on new enrollment until the safety 
review is complete.  Initiating a safety review instead 
of stoppi[INVESTIGATOR_543052] a 
mechanism to make specific 
decisions based on the criteria.  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
86 Section # and Name  [CONTACT_9353] 10.5 Appendix 5: 
Liver Safety: Suggested 
Actions and Follow up 
Assessments  Moved the acetam inophen protein adduct test 
from local laboratory table to the central 
laboratory table.  Acetaminophen protein adduct  
test will be provided by [CONTACT_543104] 10.9 Appendix 9: 
Standardized Protocols 
for the Measurement of 
Height, Weight, Waist 
Circumference, and Vital 
Signs  Clarified that for each measurement of pulse and 
blood pressure, the participant will be supi[INVESTIGATOR_543053].  To provide consistency 
throughout the protocol  
Amendment [b]: 19 January 2023  
This amendment is considered to be  nonsubstantial.  
Overall Rationale for the Amendment:  
This protocol was amended to update the timing of the final follow -up visit and the early 
discontinuation visit and other minor changes for clarity.  
Section # and Name  [CONTACT_11029]  
1.[ADDRESS_708805] 4 weeks 
but up to 6 weeks after early discont inuation  
 In response to feedback during 
European Union (EU) Paediatric 
Investigational Plan (PIP) 
review  stating that the safety 
follow -up must be planned for 
at least [ADDRESS_708806] 
4 weeks but up to 6 weeks for participants that 
discontinue ear ly, and IBT from starting at 
screening to starting at baseline.  To clarify the timing of the 
follow -up visit and the starting 
point of offering participants 
IBT 
5.2 Exclusion Criteria  Updated [18] to include type 1 and type 2 
diabetes mellitus  To clarify that participants with 
either type 1 or type 2 diabetes 
will be excluded from this 
study.  
5.3.1. Intensive 
Behavioral Therapy (IBT) 
for Chronic Weight 
Management in Children 
6-11 Years Old  Changed the total hours of IBT from 
approximately 26 hours to appr oximately 27 
hours  To clarify the total amount of 
hours IBT will be offered to 
participants  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
87 Section # and Name  [CONTACT_11029]  
6.1 Study Intervention(s) 
Administered  Added language on the paper diaries used during 
remote visits and removed the dosing 
instructions row from Table GPHV.6.[ADDRESS_708807] aced if they do not 
complete the study  
10.9 Appendix 9: 
Standardized Protocols 
for the Measurement of 
Height, Weight, Waist 
Circumference, and Vital 
Signs  Clarified that participants should be supi[INVESTIGATOR_290601] 3 minutes before measuring blood pressure 
and heart rate  To maintain consistency in the 
measurement of vital signs 
throughout the protocol  
 
Amendmen t [a]: (27-October -2022 ) 
This amendment is considered to be nonsubstantial.  
 
Overall Rationale for the Amendment  
This protocol was amended to change the definition of obesity in children of age 6 to 9 years.  
Section # and Name  [CONTACT_11029]  
1.1 Synopsis and 9.5 
Sample Size 
Determination  Added language to clarify the sample size of 6 
evaluable participants for weight category >50 
kg and 12 evaluable participants for weight 
category <50 kg  In response to feedback from 
the FDA to breakdown the 
overall sample size by [CONTACT_543105].  
1.3 Schedule of Activities  Added a row for the intensive behavioral therapy  
during the study  To captur e timing  and frequency  
of the intensive behavioral 
therapy  
4.1 Overall Design  Added intensive behavioral therapy content  To captur e intensive behavioral 
therapy  in the overall study 
design  
5. Study Population  Changed Inclusion Criterion [1] to define 
consistently the BMI that characterizes children 
with obesity for both younger (6 to 9 years, 
inclusive) and older age groups (10 to 11 years, 
inclusive).  In response to feedback from 
the European Medical Agency 
and for consistent a lignment 
with intended definition for 
Phase 3 studies.  
5.3.1 Intensive Behavioral 
Therapy (IBT) for 
Chronic Weight Added intensive behavioral therapy  To enhance study intervention 
and further increase the prospect 
of direct benefit to participants 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
88 Management in Children 
6-11 Years Old  given diet and exercise are 
critical elements in treating 
obesity  
 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
89 11. References   
[AAP IHCW] American Association of Pediatrics Institute for Healthy Childhood Weight. 
Algorithm for the assessment and management of childhood obesity in patients 2 years and 
older. 
https://ihcw.aap.org/Documents/Assessment%20%20and%20Management%20of%20Chi ldho
od%20Obesity%20Algorithm_FINAL.pdf. Published 2015. Accessed June 09, 2022 . 
[ADA] American Diabetes Association. 13. Children and adolescents: standards of medical care 
in diabetes 2021. Diabetes Care . 2021;44(suppl 1):S180 -S199. https://doi.org/10.233 7/dc20 -
S013  
[ADA] American Diabetes Association . Glycemic targets: standards of medical care in 
diabetes  - 2020. Diabetes Care . 2020 ;43(suppl 1):S66 -S76. 
https://doi.org/ 10.2337/dc20 -S006  
[AMA] American Medical Association. American Medical Association House of Delegates 
resolution: 420 (A -13): recognition of obesity as a disease. May 2013. Accessed May 21, 
2020. https://media.npr.org/documents/2013/jun/ama -resolution -obesity.pdf   
[APA] American Psychological Association, Clinical Practice Guideline Panel. (2018). Clinical 
practice guideline for multicomponent behavioral treatment of obesity and overweight in 
children and adolescents: Current state of the evidence and research needs. 
https://www.apa.org/about/offices/directorates/guidelines/obesity -clinical -practice -
guideline.pdf Accessed 17 October 2022.  
Apovian CM, Aronne LJ, Bessesen DH, et al.  Pharmacological management of obesity: an 
endocrine society clinical practice guideline J Clin Endocrinol Metab. 2015;100(2):342 -362. 
https://doi.org/10.1210/jc.[ADDRESS_708808] GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: an endocrine 
society clinical practice guideline based on expert opi[INVESTIGATOR_1649]. J Clin Endocri nol Metab . 
2008;93(12):4576 -4599. https://doi.org/10.1210/jc.2007 -2458  
Banks PA, Freeman ML; Practice Parameters Committee of the American College of 
Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol . 
2006;101(10):2379 -2400 . https://doi.org/ 10.1111/j.1572 -0241.2006.[ZIP_CODE].x  
Barlow SE. Expert committee recommendations regarding the prevention, assessment and 
treatment of child and adolescent overweight and obesity: summary report. Pediatrics . 
2007;120(suppl 4):S164 -S192.  
Bayer SA, Altman J, Russo RJ, Zhang X. Timetables of neurogenesis in the human brain based 
on experimentally determined patterns in the rat. Neurotoxicology . 1993;14(1):83 -144. 
Beck MJ, Padgett E, Bowman CJ, et al. Nonclinical  juvenile toxicity testing. In : Hood RD, 
editor. Developmental and Reproductive Toxicology: A Practical Approach. 2nd ed.  CRC 
Press; 2006:p 263 -328. 
Brown JD, Buscemi J, Milsom V, et al. Effects on cardiovascular risk factors of weight losses 
limited to 5 -10. Transl Behav Med . 2016;6(3 ):339 -346. https://doi.org/10.1007/s13142 -015-
0353 -9 
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
90 Crocker MK, Yanovski JA. Pediatric obesity: etiology and treatment. Endocrinol Metab Clin 
North Am . 2009;38(3):525 -548. https://dx.doi.org/10.1016%2Fj.ecl.2009.06.007  
Durkin N, Desai AP. What is the evid ence for paediatric/adolescent bariatric surgery? Curr Obes 
Rep. 2017;6(3):278 -285. https://doi.org/10.1007/s13679 -017-0277 -4 
Farris JW, Taylor L, Williamson M, Robinson C. A 12 -week interdisciplinary intervention 
program for children who are obese. Cardio pulm Phys Ther J.  2011;22(4):12 -20. 
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 
2 diabetes (REWIND): a double -blind, randomized placebo -controlled trial. Lancet. 
2019;394([ZIP_CODE]):121 -130. https://doi.org/10.1016/S0140 -6736(19)[ADDRESS_708809] of sibutramine on weight maintenance after weight 
loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and 
Maintenance.  Lancet . 2000;356 (9248):2119‐2125. https://doi.org/10.1016/s0140 -
6736(00)[ZIP_CODE] -7 
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of 
obesity [published online ahead of print, Jun 4 , 2022 ]. N Engl J Med . 
https://doi.org/ 10.1056/NEJMoa2206 038 
Jastreboff AM, Kotz CM, Kahan S, et al. Obesity as a disease: The Obesity Society 2018 
position statement. Obesity . 2019;27(1):7 -9. https://doi.org/10.1002/oby.[ZIP_CODE]  
Jensen MD, Ryan DH, Donato KA, et al; Expert Panel Members. Executive summary: guidelines 
(2013) for the management of overweight and obesity in adults: a report of the American 
College of Cardiology/American Heart Association Task Force on Practice Guidel ines and the 
Obesity Society published by [CONTACT_543106]/American Heart Association Task Force on Practice Guidelines. Based on a 
systematic review from the Obesity Expert Panel, 2013. Obesity  (Silver Spring) . 
2014;2 2:(suppl 2):S5 -S39. https://doi.org/10.1002/oby.[ZIP_CODE]  
Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and 
cardiovascular risk factors. NEJM . 2011;365(20):1876 -1885. 
https://doi.org/10.1056/nejmoa1010112  
Knowler WC, Barret t-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes 
with lifestyle intervention or metformin. N Engl J Med.  2002;346(6):393 -403. 
https://doi.org/10.1056/NEJMoa012512  
Koizumi M, Takada T, Kawarada Y , et al. JPN guidelines for the management of acute 
pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg . 
2006;13(1):25 -32. https://doi.org/ 10.1007/s00534 -005-1048 -2 
Kolotkin RL, Andersen JR. A systematic review of reviews: explor ing the relationship between 
obesity, weight loss and health -related quality of life. Clin Obes . 2017;7(5):273‐289. 
https://doi.org/10.1111/cob.[ZIP_CODE]  
Krebs NF, Himes JH, Jacobson D, et al. Assessment of child and adolescent overweight and 
obesity. Pediatri cs. 2007;120(S4):S193 -228. https://doi.org/10.1542/peds.2007 -2329d  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
91 Kritchevsky SB, Beavers KM, Miller ME, et al. Intentional weight loss and all -cause mortality: a 
meta -analysis of randomized clinical trials. PLoS One . 2015;10(3):e0121993. 
https://doi.org/ 10.1371/journal.pone.0121993  
Lauby -Secretan B, Scoccianti C, Loomis D, et al; International Agency for Research on Cancer 
Handbook Working Group. Body fatness and cancer  - viewpoint of the IARC Working Group. 
N Engl J Med.  2016;375(8):794 -798. https://doi. org/10.1056/NEJMsr1606602  
Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body 
weight. N Engl J Med . 1995;332(10):621‐628. 
https://doi.org/10.1056/NEJM199503093321001  
Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child . 
1970;45(239):13 -23. https://doi.org/ 10.1136/adc.45.239.13  
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch. Dis Child . 
1969;44(23 5):291 -303. https://doi.org/10.1136/adc.44.235.291  
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with 
type 2 diabetes. N Engl J Med.  2016a;375(19):1834 -1844. 
https://doi.org/ 10.1056/NEJMoa1607141  
Marso SP, Daniels  GH, Brown -Frandsen K, et al. Liraglutide and cardiovascular outcomes in 
type 2 diabetes. N Engl J Med.  2016b;375(4):311 -322. 
https://doi.org/10.1056/NEJMoa1603827  
Mayr HL, Cohen F, Isenring E, et al. Multidisciplinary lifestyle intervention in children an d 
adolescents – results of the project GRIT (growth, resilience, insights, thrive) pi[INVESTIGATOR_799]. BMC 
Pediat r. 2020;20(174):1 -16. 
Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight 
reduction. Obes Res . 2000;8(3):270 -278. https://doi.org/10.1038/oby.2000.32  
Nauck M. Incretin therapi[INVESTIGATOR_014]: highlighting common features and differences in the modes of 
action of glucagon -like peptide -1 receptor agonists and dipeptidyl peptidase -4 inhibitors. 
Diabetes Obes Metab . 2016;18(3):203 -216. https://doi.org/ 10.1111/dom.[ZIP_CODE]  
Rice D, Barone Jr S. Critical periods of vulnerability for the developi[INVESTIGATOR_543054]: 
evidence from humans and animal models. Environ Health Perspect . 2000;108(suppl 
3):511 -533. https://doi.org/10. 1289/ehp.00108s3511  
Rodier PM. Chronology of neuron development: animal studies and their clinical implications. 
Develop Med Child Neurol.  1980;22(4):525 -545. https://doi.org/10.1111/j.1469 -
8749.1980.tb04363.x  
Skinner AC, Ravanbakht SN, Skelton JA, et al. Prevalence of obesity and severe obesity in US 
children, 1999 -2016. Pediatrics . 2018;141(3):e20173 459. https://doi.org/10.1542/peds.2017 -
3459  
Smith SR, Weissman NJ, Anderson CM, et al .; Behavioral Modification and Lorcaserin for 
Overweight and Obesity Mana gement (BLOOM) Study Group. Multicenter, placebo -
controlled trial of lorcaserin for weight management. N Engl J Med . 2010;363(3):245‐256. 
https://doi.org/10.1056/NEJMoa0909809  
Approved on 16 Nov 2023 GMT
CONFIDENTIAL  I8F-MC-GPHV (e) 
92 Steinberg WM, Buse JB, Ghorbani MLM, et al. ; LEADER Steering Committee; LEADER T rial 
Investigators. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated 
with liraglutide: results from the LEADER randomized trial. Diabetes Care . 2017a;40(7):966 -
972 [Erratum in:  Diabetes Care . 2018;41(7):1538] . https://doi.org/ 10.2337/dc16 -[ADDRESS_708810] of liraglutide on amylase, lipase, and 
acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or 
type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development 
program. Diabetes Care . 2017b;40(7):830 -848. https://doi.org/10.2337/dc16 -2684  
Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity - assessment, treatment and 
prevention: an endoc rine society clinical practice guideline.  J Clin Endocrinol Metab. 
2017;102(3):709 -757. https://doi.org/10.1210/jc.[ADDRESS_708811] LA, Delbridge E, et al. Long -term persistence of hormonal adaptations 
to weight loss. N Engl J Med . 2011;3 65(17):1597‐1604. 
https://doi.org/10.1056/NEJMoa1105816  
Swift DL, McGee JE, Earnest CP, et al. The effects of exercise and physical activity on weight 
loss and maintenance. Prog Cardiovasc Dis . 2018;61(2):206‐213. 
https://doi.org/10.1016/j.pcad.2018.07.014  
[USPSTF] US Preventive Services Task Force. Screening for obesity in children and 
adolescents: US Preventive Services Task Force recommendation statement. JAMA . 
2017;317(23):2417 -2426.  
van Bloemendaal L, Ten Kulve JS, la Fleur SE, et al. Effects of glucag onlike  peptide 1 on 
appetite and body weight: focus on the CNS. J Endocrinol.  2014;221(1):T1 -T16. 
https:// doi.org/10.1530/JOE -13-0414  
Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with 
liraglutide after low -calorie -diet-induced weight loss: the SCALE Maintenance randomized 
study. Int J Obes . 2013;37(11):1443‐1451. https://doi.org/10.1038/ijo.2013.120  
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequently repeated glucose measurements 
overestimate the incidence of inpatien t hypoglycemia and severe hyperglycemia. J Diabetes 
Sci Technol . 2010;4(3):577 -582. https:// doi.org/ 10.1177/193229681000400311  
[WHO] World Health Organization. The WHO STEPWise approach to noncommunicable 
disease risk factor surveillance. WHO STEPS Surveillance Manual. Updated January 26, 
2017. Accessed March 13, 2020. 
https://www.who.int/ncds/surveillance/steps/STEPS_Manual.pdf  
Approved on 16 Nov 2023 GMT
Signature [CONTACT_11032]-CLIN-110264 v3.0
Signature [CONTACT_11032]-CLIN-110264 v3.0Approval
16-Nov-2023 11:44:37 GMT[PHONE_006]
Approval
cian
16-Nov-2023 21:11:04 GMT[PHONE_006]
Approved on 16 Nov 2023 GMT
[COMPANY_003]
[COMPANY_003]